PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16307210-2	2005	Pindolol, a betablocker with weak partial 5-HT1A receptor agonist activity has been shown to produce a more rapid onset of antidepressant action of SSRIs.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	42-57
16452992-0	2006	Blockade of 5-HT1A receptors by (+/-)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioral approaches in 5-HT1A receptor knockout mice.	Pindolol	32-46	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	12-18
16452992-0	2006	Blockade of 5-HT1A receptors by (+/-)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioral approaches in 5-HT1A receptor knockout mice.	Pindolol	32-46	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	12-27
16452992-8	2006	The selective 5-HT1A receptor antagonist, WAY-100635 (0.5 mg/kg), or (+/-)-pindolol (5 and 10 mg/kg) potentiated the effects of Prx (4 mg/kg) on cortical [5-HT]ext in 5-HT1A+/+, but not in 5-HT1A-/- mice.	Pindolol	69-83	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	167-173
16452992-12	2006	These findings using 5-HT1A-/- mice confirm that (+/-)-pindolol behaves as an antagonist of 5-HT1A autoreceptor in mice, but its blockade of paroxetine-induced antidepressant-like effects in the FST may be due to its binding to other neurotransmitter receptors.	Pindolol	49-63	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	92-98
16574446-8	2006	The D115E mutant with pindolol displays a greater DeltaDeltaE(EL) and TM interactions than for the wild-type B2AR with pindolol.	Pindolol	22-30	adrenoceptor beta 2	Homo sapiens	109-113
16574446-8	2006	The D115E mutant with pindolol displays a greater DeltaDeltaE(EL) and TM interactions than for the wild-type B2AR with pindolol.	Pindolol	119-127	adrenoceptor beta 2	Homo sapiens	109-113
16475955-1	2006	Pindolol, a partial beta-adrenoceptor/5-HT1A receptor antagonist was first used to accelerate the onset of action of antidepressant drugs in 1994.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	38-53
16475955-5	2006	Pindolol was initially used due to its ability to block 5-HT1A receptor-mediated responses and to enhance the neurochemical effects of SSRIs.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	56-71
16475955-6	2006	In transfected cells, however, pindolol is a weak (20-25%) partial agonist at 5-HT1A receptors and, as such, its actions greatly depend on the system used.	Pindolol	31-39	5-hydroxytryptamine receptor 1A	Homo sapiens	78-84
16475955-8	2006	Positron emission tomography (PET) scan studies have shown that pindolol displays a preferential occupancy of pre- vs. postsynaptic 5-HT1A receptors, although the overall occupancy is lower than desirable, which suggests that higher doses (e.g., 15 mg/day) may be more effective than the currently used 7.5 mg daily dosage.	Pindolol	64-72	5-hydroxytryptamine receptor 1A	Homo sapiens	132-138
16475955-9	2006	However, given the complex pharmacology of pindolol, it is hoped that new developments in this field can proceed through the use of a) selective and silent 5-HT1A receptor antagonists in combination with SSRIs, or b) dual action agents (SSRI+5-HT1A receptor blockers).	Pindolol	43-51	5-hydroxytryptamine receptor 1A	Homo sapiens	156-171
15777775-2	2005	We have previously demonstrated that pindolol, a beta-adrenoceptor blocker/5-hydroxytryptamine(1A/1B) receptor antagonist, enhanced tramadol antinociception and that the selective 5-HT1A agonist 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) reduced it.	Pindolol	37-45	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	180-186
15648095-8	2005	dose of pindolol that has been used in all but one of these investigations may be suboptimal for achieving reliable and significant occupancy of 5-HT1A autoreceptors and may explain the contradictory nature of the results of investigations of pindolol augmentation.	Pindolol	8-16	5-hydroxytryptamine receptor 1A	Homo sapiens	145-151
15127080-0	2004	Preferential 5-HT1A autoreceptor occupancy by pindolol is attenuated in depressed patients: effect of treatment or an endophenotype of depression?	Pindolol	46-54	5-hydroxytryptamine receptor 1A	Homo sapiens	13-19
15127080-1	2004	Using positron emission tomography and the selective 5-HT1A receptor radioligand [11C]WAY100635, we previously demonstrated a preferential occupancy of 5-HT1A autoreceptors, compared to postsynaptic receptors by pindolol in healthy volunteers.	Pindolol	212-220	5-hydroxytryptamine receptor 1A	Homo sapiens	53-59
15127080-3	2004	In this study, we have examined the preferential occupancy by pindolol of 5-HT1A autoreceptors, following three different pindolol regimes (10 mg single dose, 2.5 mg t.i.d., and 5 mg t.i.d., in 15 depressed patients on SSRIs.	Pindolol	62-70	5-hydroxytryptamine receptor 1A	Homo sapiens	74-80
15013031-7	2004	RESULTS: Pindolol significantly antagonized ACTH, PRL, GH and temperature responses to flesinoxan and ritanserin exhibited similar activity on PRL and ACTH responses.	Pindolol	9-17	prolactin	Homo sapiens	50-53
15093954-4	2004	Since the release of cortisol and prolactin is under serotonergic control, we hypothesized that pindolol augmentation of synaptic 5-HT concentrations produced by an SSRI in humans should lead to enhanced SSRI-induced cortisol and prolactin responses.	Pindolol	96-104	prolactin	Homo sapiens	34-43
15093954-4	2004	Since the release of cortisol and prolactin is under serotonergic control, we hypothesized that pindolol augmentation of synaptic 5-HT concentrations produced by an SSRI in humans should lead to enhanced SSRI-induced cortisol and prolactin responses.	Pindolol	96-104	prolactin	Homo sapiens	230-239
14533141-0	2003	Effect of pindolol and milnacipran versus milnacipran and placebo on plasma prolactin and adrenocorticotrophic hormone in depressed subjects.	Pindolol	10-18	prolactin	Homo sapiens	76-85
14720318-1	2004	The 5-HT1A/beta-adrenoceptor ligand (+/-)pindolol has been used in clinical trials to enhance the antidepressant effect of selective serotonin (5-HT) reuptake inhibitors (SSRIs).	Pindolol	41-49	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10
14720318-2	2004	The accelerating effect of (+/-)pindolol is thought to derive from its blockade of the SSRI-induced, 5-HT1A autoreceptor-mediated inhibition of serotonergic cell firing and 5-HT release.	Pindolol	27-40	5-hydroxytryptamine receptor 1A	Homo sapiens	101-107
14720318-5	2004	In these regions, enriched in 5-HT1A receptors, (+/-)pindolol antagonized the stimulation of [35S]GTPgammaS binding induced by 5-HT in a concentration-dependent manner.	Pindolol	53-61	5-hydroxytryptamine receptor 1A	Homo sapiens	30-36
14720318-7	2004	This suggests a higher potency of (+/-)pindolol at somatodendritic 5-HT1A receptors compared to post-synaptic 5-HT1A sites.	Pindolol	34-47	5-hydroxytryptamine receptor 1A	Homo sapiens	67-73
15006431-1	2004	Selective serotonin reuptake inhibitor (SSRI) augmentation with the 5-HT1A antagonist pindolol has met with mixed results.	Pindolol	86-94	5-hydroxytryptamine receptor 1A	Homo sapiens	68-74
15006431-2	2004	Recent studies using positron emission tomography (PET) suggest that pindolol doses used in these studies were too low to effect 5-HT1A autoreceptor blockade.	Pindolol	69-77	5-hydroxytryptamine receptor 1A	Homo sapiens	129-135
14729220-1	2004	Based on its proposed ability to block the effect of selective serotonin reuptake inhibitors (SSRIs) on the firing rate of serotonergic neurons, the 5-HT1A partial agonist/beta-adrenergic antagonist pindolol has been examined in clinical trials for its ability to enhance the efficacy of SSRIs.	Pindolol	199-207	5-hydroxytryptamine receptor 1A	Rattus norvegicus	149-155
12944320-5	2003	Conversely, OCT1 had a higher affinity for tyramine and pindolol than did OCT2 (21.2 and 2.4 vs. 361 and 50 microM, respectively).	Pindolol	56-64	solute carrier family 22 member 1	Oryctolagus cuniculus	12-16
14608456-0	2003	Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors.	Pindolol	38-50	adrenoceptor beta 1	Homo sapiens	108-126
14608456-2	2003	Recent work indicates the existence of a (-)-propranolol-resistant site of the cardiac beta(1)-adrenoceptor and we propose that it mediates the cardiostimulation evoked by (-)-pindolol.	Pindolol	172-184	adrenoceptor beta 1	Homo sapiens	87-107
14608456-7	2003	The positive inotropic effects of (-)-pindolol were resistant to blockade by L-748,337 (100 nM), a beta(3)-adrenoceptor antagonist.	Pindolol	34-46	adrenoceptor beta 3	Homo sapiens	99-119
14608456-12	2003	We conclude that the cardiostimulant effects of (-)-pindolol in human atrial myocardium are mediated through a (-)-propranolol-resistant site of the beta(1)-adrenoceptor with low affinity for (-)-pindolol.	Pindolol	48-60	adrenoceptor beta 1	Homo sapiens	149-169
14608456-12	2003	We conclude that the cardiostimulant effects of (-)-pindolol in human atrial myocardium are mediated through a (-)-propranolol-resistant site of the beta(1)-adrenoceptor with low affinity for (-)-pindolol.	Pindolol	192-204	adrenoceptor beta 1	Homo sapiens	149-169
14608456-13	2003	In contrast, (-)-pindolol blocks the effects of catecholamines through a high-affinity site of the beta(1)-adrenoceptor.	Pindolol	13-25	adrenoceptor beta 1	Homo sapiens	99-119
14533141-2	2003	The present study analyses the relationship between plasma prolactin (PRL) and ACTH levels and changes in relation to a milnacipran and pindolol combination versus milnacipran plus placebo.	Pindolol	136-144	prolactin	Homo sapiens	59-68
14533141-2	2003	The present study analyses the relationship between plasma prolactin (PRL) and ACTH levels and changes in relation to a milnacipran and pindolol combination versus milnacipran plus placebo.	Pindolol	136-144	prolactin	Homo sapiens	70-73
12660886-8	2002	CONCLUSIONS: First, patients with essential hypertension are characterized by higher plasma leptin levels as compared with normotensive healthy subjects; second, suppressive effect of pindolol on leptinemia may be of pathophysiological relevance in the course of weight gain during beta-blocker therapy.	Pindolol	184-192	leptin	Homo sapiens	92-98
12880941-1	2003	BACKGROUND: It has been suggested that treatment with selective serotonin reuptake inhibitors (SSRIs) in combination with pindolol, a partial agonist at the 5-HT(1A) receptor, may produce a fast antidepressant response.	Pindolol	122-130	5-hydroxytryptamine receptor 1A	Homo sapiens	157-174
12880941-6	2003	CONCLUSIONS: A nearly complete blockade of the 5-HTT is obtained already after the first dose only with paroxetine, explaining why the latency reducing effect of pindolol preferentially is seen when pindolol is combined with paroxetine.	Pindolol	162-170	solute carrier family 6 member 4	Homo sapiens	47-52
12880941-6	2003	CONCLUSIONS: A nearly complete blockade of the 5-HTT is obtained already after the first dose only with paroxetine, explaining why the latency reducing effect of pindolol preferentially is seen when pindolol is combined with paroxetine.	Pindolol	199-207	solute carrier family 6 member 4	Homo sapiens	47-52
12589521-0	2003	EEG effects of buspirone and pindolol: a method of examining 5-HT1A receptor function in humans.	Pindolol	29-37	5-hydroxytryptamine receptor 1A	Homo sapiens	61-76
12589521-4	2003	Animal research suggests that pindolol is an agonist at these receptors but an antagonist at postsynaptic 5-HT(1A) receptors.	Pindolol	30-38	5-hydroxytryptamine receptor 1A	Homo sapiens	106-113
12589521-5	2003	OBJECTIVE: We postulated that while pindolol would antagonise known postsynaptic mediated neuroendocrine responses to the 5-HT(1A) agonist buspirone, both drugs would have a similar effect on the EEG frequency spectrum.	Pindolol	36-44	5-hydroxytryptamine receptor 1A	Homo sapiens	122-129
12589521-10	2003	CONCLUSIONS: The data obtained are consistent with the EEG effects of buspirone and pindolol being mediated by somatodendritic 5-HT(1A) receptors, in contrast to the neuroendocrine response, which is known to be mediated by postsynaptic receptors.	Pindolol	84-92	5-hydroxytryptamine receptor 1A	Homo sapiens	127-134
12536263-2	2003	Animal studies have suggested that this increased response occurs because of 5HT(1A) antagonist properties of pindolol, which in combination with a serotonergic antidepressant produces a synergistic increase in 5HT in the synapse.	Pindolol	110-118	5-hydroxytryptamine receptor 1A	Homo sapiens	77-83
12900854-4	2003	The chicken alpha(1)-AGP showed higher resolution for eperisone, pindolol and tolperisone than cd-alpha(1)-AGP or recombinant alpha(1)-AGP.	Pindolol	65-73	orosomucoid 1 (ovoglycoprotein)	Gallus gallus	12-24
14615704-3	2003	Pindolol, an antagonist at somatodendritic pre-synaptic 5HT1A receptors has been investigated as a potential accelerator or potentialisator of antidepressant response.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	56-61
12616336-1	2003	Two forms of the activated beta1-adrenoceptor exist, one that is stabilized by (-)-noradrenaline and is sensitive to blockade by (-)-propranolol and another which is stabilized by partial agonists such as (-)-pindolol and (-)-CGP 12177 but is relatively insensitive to (-)-propranolol.	Pindolol	205-217	adrenoceptor beta 1	Homo sapiens	27-45
12166089-0	2002	[Effect of (+/-)-pindolol on the central 5-HT1A receptor by the use of in vivo microdialysis and hippocampal slice preparations].	Pindolol	11-25	5-hydroxytryptamine receptor 1A	Homo sapiens	41-56
12166089-2	2002	In this study we have investigated the effect of (+/-)-pindolol on both pre- and postsynaptic 5-HT1A receptors using in vivo microdialysis and hippocampal slice preparations.	Pindolol	49-63	5-hydroxytryptamine receptor 1A	Homo sapiens	94-100
12166089-1	2002	Although it is suggested that (+/-)-pindolol, a beta-adrenergic/5-HT1A receptor antagonist, may enhance the efficacy of selective serotonin reuptake inhibitors (SSRI), the results of double-blind studies are contradictory and recent animal studies suggest that (+/-)-pindolol may act as a partial agonist to the 5-HT1A receptor.	Pindolol	30-44	5-hydroxytryptamine receptor 1A	Homo sapiens	64-79
12166089-3	2002	(+/-)-pindolol and flesinoxan, a 5-HT1A receptor full agonist, significantly decreased the extracellular levels of 5-HT in the raphe and prefrontal cortex.	Pindolol	0-14	5-hydroxytryptamine receptor 1A	Homo sapiens	33-48
12166089-5	2002	The effect of 5-HT and other 5-HT1A receptor agonists accompanied the increase in paired-pulse facilitation (ppf) induced by short-interval two stimuli and were reversed by the coadministration of the 5-HT1A receptor agonist, NAN-190, but not by (+/-)-pindolol.	Pindolol	246-260	5-hydroxytryptamine receptor 1A	Homo sapiens	29-44
12166089-1	2002	Although it is suggested that (+/-)-pindolol, a beta-adrenergic/5-HT1A receptor antagonist, may enhance the efficacy of selective serotonin reuptake inhibitors (SSRI), the results of double-blind studies are contradictory and recent animal studies suggest that (+/-)-pindolol may act as a partial agonist to the 5-HT1A receptor.	Pindolol	30-44	5-hydroxytryptamine receptor 1A	Homo sapiens	312-327
12166089-5	2002	The effect of 5-HT and other 5-HT1A receptor agonists accompanied the increase in paired-pulse facilitation (ppf) induced by short-interval two stimuli and were reversed by the coadministration of the 5-HT1A receptor agonist, NAN-190, but not by (+/-)-pindolol.	Pindolol	246-260	5-hydroxytryptamine receptor 1A	Homo sapiens	201-216
11330332-0	2001	Pindolol antagonises G-protein activation at both pre- and postsynaptic serotonin 5-HT1A receptors: a.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	82-88
12166089-7	2002	These results suggest that (+/-)-pindolol acts as a partial agonist to the somatodendritic 5-HT1A receptor in the raphe, whereas it may have no action on the postsynaptic 5-HT1A receptor in the hippocampus.	Pindolol	27-41	5-hydroxytryptamine receptor 1A	Homo sapiens	91-106
11888550-12	2002	Finally, in line with species differences, the affinities of several ligands including CP93,129, RU24,969, (-)-pindolol and (-)-propanolol in rat 5-HT(1B) sites were markedly different to guinea pig 5-HT(1B) sites labelled with [3H]GR125,743.	Pindolol	107-119	5-hydroxytryptamine receptor 1B	Rattus norvegicus	146-153
11713611-4	2001	OBJECTIVE: To characterise the dual action of buspirone in stimulating the secretion of prolactin by blocking the 5-HT(1A) action with the 5-HT1A antagonist action of pindolol.	Pindolol	167-175	5-hydroxytryptamine receptor 1A	Homo sapiens	139-145
11713611-7	2001	RESULTS: Pindolol alone caused a small but significant reduction (18%) in the tonic release of prolactin.	Pindolol	9-17	prolactin	Homo sapiens	95-104
11713611-8	2001	Buspirone alone produced a robust prolactin response which was reduced to approximately half by pindolol pre-treatment.	Pindolol	96-104	prolactin	Homo sapiens	34-43
11713611-9	2001	Pindolol pre-treatment also, on average, delayed the onset and peak of the prolactin response.	Pindolol	0-8	prolactin	Homo sapiens	75-84
11713611-12	2001	However, if two challenges are carried out, one with buspirone and the other with buspirone plus pindolol, quantitative measures can be made of the sensitivity of both the 5-HT(1A) and the putative D(2) pathways controlling prolactin release.	Pindolol	97-105	prolactin	Homo sapiens	224-233
11292445-9	2001	The potentiating action of 5-HT1A, 5-HT2A/1C or 5-HT3 receptor agonist on 3alpha,5alpha-THP induced catalepsy was not blocked by prior administration of sub-effective dose (1 mg/kg, s.c.) of their respective receptor antagonists pindolol, ritanserin or ondansetron or by pretreatment with serotonergic neurotoxin 5,7-DHT (100 microg/mouse, i.c.v.).	Pindolol	229-237	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	27-33
11729033-1	2001	OBJECTIVE: Positron emission tomography (PET) was used to examine whether the dose of pindolol used to augment antidepressant medication achieves a significant occupancy of the serotonin type 1A (5-HT(1A)) autoreceptor in depressed patients receiving medication.	Pindolol	86-94	5-hydroxytryptamine receptor 1A	Homo sapiens	196-203
11457419-5	2001	METHODS: Using microdialysis and jugular vein catheterization, we studied the ability of systemically administered pindolol to antagonize central 5-HT(1A) and beta-adrenoceptors, while simultaneously monitoring pindolol plasma and brain concentrations.	Pindolol	115-123	5-hydroxytryptamine receptor 1A	Cavia porcellus	146-153
11457419-8	2001	CONCLUSIONS: At plasma levels that are observed in patients after 2.5 mg three times a day ( approximately 60 nmol/L), pindolol produces only a partial blockade of presynaptic 5-HT(1A) autoreceptors and does not augment the SSRI-induced 5-HT increase in the guinea pig brain.	Pindolol	119-127	5-hydroxytryptamine receptor 1A	Homo sapiens	176-183
11330332-3	2001	Herein, we evaluated the actions of pindolol at 5-HT1A autoreceptors and specific populations of postsynaptic 5-HT1A receptors employing [35S]GTPgammaS autoradiography, a measure of receptor-mediated G-protein activation.	Pindolol	36-44	5-hydroxytryptamine receptor 1A	Homo sapiens	48-54
11330332-6	2001	In the dentate gyrus, lateral septum and entorhinal cortex, structures enriched in postsynaptic 5-HT1A receptors, 8-OH-DPAT (1 microM) and 5-HT (10 microM) also elicited a marked increase in [35S]GTPgammaS binding which was likewise blocked by pindolol.	Pindolol	244-252	5-hydroxytryptamine receptor 1A	Homo sapiens	96-102
11330332-9	2001	In conclusion, these data suggest that, as characterised by [35S]GTPgammaS autoradiography, and compared with 5-HT and 8-OH-DPAT, pindolol possesses low efficacy at both pre- and postsynaptic 5-HT1A receptors.	Pindolol	130-138	5-hydroxytryptamine receptor 1A	Homo sapiens	192-198
11236069-10	2001	Pindolol, with its dual beta and 5-HT1A blocking effect ameliorated both number and severity of aggressive acts.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	33-39
11199945-1	2001	In a controlled trial, the beta-adrenoceptor/5-hydroxytryptamine-1A (5-HT1A) receptor antagonist pindolol accelerated and enhanced the antidepressant effect of fluoxetine.	Pindolol	97-105	5-hydroxytryptamine receptor 1A	Homo sapiens	27-67
11166513-1	2001	Augmentation of selective serotonin reuptake inhibitors (SSRIs) therapy by the 5-HT(1A) receptor agent pindolol may reduce the delay between initiation of antidepressant treatment and clinical response.	Pindolol	103-111	5-hydroxytryptamine receptor 1A	Homo sapiens	79-96
11199945-1	2001	In a controlled trial, the beta-adrenoceptor/5-hydroxytryptamine-1A (5-HT1A) receptor antagonist pindolol accelerated and enhanced the antidepressant effect of fluoxetine.	Pindolol	97-105	5-hydroxytryptamine receptor 1A	Homo sapiens	69-85
11199945-5	2001	Mean values were approximately 26 nM, a concentration higher than the Ki of (-)pindolol for human 5-HT1A autoreceptors (11 nM).	Pindolol	79-87	5-hydroxytryptamine receptor 1A	Homo sapiens	98-104
11063976-4	2000	Because the 5-HT(1A) antagonist pindolol may hasten antidepressant effects of selective serotonin reuptake inhibitor medications, its receptor occupancy has been measured in both presynaptic and postsynaptic sites.	Pindolol	32-40	5-hydroxytryptamine receptor 1A	Homo sapiens	12-19
11444761-5	2001	The addition of pindolol, which blocks 5-HT1A receptors, to SSRI treatment decouples the feedback inhibition of 5-HT neuron firing and accelerates and enhances the antidepressant response.	Pindolol	16-24	5-hydroxytryptamine receptor 1A	Homo sapiens	39-45
11243572-4	2001	In the presence of (+/-)-propranolol (1 microM), the non-selective beta1-, beta2- and beta3-adrenoceptor antagonist (+/-)-bupranolol (30 microM) induced a rightward shift of the concentration-response curves for (+/-)-pindolol (apparent pA2 = 5.41 +/- 0.06).	Pindolol	212-226	beta-2 adrenergic receptor	Cavia porcellus	67-104
11077069-8	2001	Both the degree of 5-HT(1A) receptor activation by 8-OH-DPAT and (-)-pindolol, and its inhibition by spiperone, strongly correlate (r(2): 0.78-0.81) with the octanol/water partition coefficients of the mutated amino acid at position 351 of the G(alphai3) protein.	Pindolol	65-77	5-hydroxytryptamine receptor 1A	Homo sapiens	19-36
11063979-1	2000	Preclinical studies suggest that augmentation of selective serotonin (5-HT) reuptake inhibitors by the 5-HT(1A) receptor agent pindolol might reduce the delay between initiation of treatment and antidepressant response, an effect largely mediated by blockade of 5-HT(1A) autoreceptors in the dorsal raphe nuclei.	Pindolol	127-135	5-hydroxytryptamine receptor 1A	Homo sapiens	103-120
11063979-1	2000	Preclinical studies suggest that augmentation of selective serotonin (5-HT) reuptake inhibitors by the 5-HT(1A) receptor agent pindolol might reduce the delay between initiation of treatment and antidepressant response, an effect largely mediated by blockade of 5-HT(1A) autoreceptors in the dorsal raphe nuclei.	Pindolol	127-135	5-hydroxytryptamine receptor 1A	Homo sapiens	103-110
11063979-3	2000	Recent positron emission tomography studies investigating the occupancy of 5-HT(1A) receptors in humans by pindolol have shown that at the dose used most often in clinical trials the occupancy is low and variable, which might explain the inconsistent clinical results.	Pindolol	107-115	5-hydroxytryptamine receptor 1A	Homo sapiens	75-82
11063979-4	2000	Positron emission tomography studies also suggest that pindolol might be more potent at blocking 5-HT(1A) autoreceptors than at blocking postsynaptic receptors, a property that may be useful in this pharmacologic strategy.	Pindolol	55-63	5-hydroxytryptamine receptor 1A	Homo sapiens	97-104
10962261-0	2000	Positron emission tomography study of pindolol occupancy of 5-HT(1A) receptors in humans: preliminary analyses.	Pindolol	38-46	5-hydroxytryptamine receptor 1A	Homo sapiens	60-67
10998110-0	2000	Pindolol excites dopaminergic and adrenergic neurons, and inhibits serotonergic neurons, by activation of 5-HT1A receptors.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-112
10998110-3	2000	In analogy to the serotonin1A (5-HT1A) agonist, 8-OH-DPAT (-100%), pindolol dose-dependently (0.063- 1.0 mg/kg) decreased (-70%) the firing rate of serotonergic neurons.	Pindolol	67-75	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
10998110-4	2000	The inhibitory action of pindolol was abolished by the selective 5-HT1A antagonist, WAY-100,635 (0.031 mg/kg).	Pindolol	25-33	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
10998110-12	2000	In conclusion, via engagement of 5-HT1A receptors, pindolol inhibits serotonergic, and activates dopaminergic and adrenergic, neurons in anaesthetized rats.	Pindolol	51-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	33-39
11022403-1	2000	OBJECTIVE: Given reports that (+/-)pindolol, a beta-adrenergic-5-HT1A/1B receptor antagonist, accelerates the onset of the therapeutic effect of certain antidepressant drugs in major depression, the aim of this study was to assess the effect of sustained (+/-)pindolol administration on the sensitivity of pre- and postsynaptic 5-HT1A receptors, terminal 5-HT1B autoreceptors and on overall 5-HT neurotransmission.	Pindolol	30-43	5-hydroxytryptamine receptor 1A	Homo sapiens	63-69
11022403-1	2000	OBJECTIVE: Given reports that (+/-)pindolol, a beta-adrenergic-5-HT1A/1B receptor antagonist, accelerates the onset of the therapeutic effect of certain antidepressant drugs in major depression, the aim of this study was to assess the effect of sustained (+/-)pindolol administration on the sensitivity of pre- and postsynaptic 5-HT1A receptors, terminal 5-HT1B autoreceptors and on overall 5-HT neurotransmission.	Pindolol	30-43	5-hydroxytryptamine receptor 1A	Rattus norvegicus	328-334
11022403-1	2000	OBJECTIVE: Given reports that (+/-)pindolol, a beta-adrenergic-5-HT1A/1B receptor antagonist, accelerates the onset of the therapeutic effect of certain antidepressant drugs in major depression, the aim of this study was to assess the effect of sustained (+/-)pindolol administration on the sensitivity of pre- and postsynaptic 5-HT1A receptors, terminal 5-HT1B autoreceptors and on overall 5-HT neurotransmission.	Pindolol	30-43	5-hydroxytryptamine receptor 1B	Rattus norvegicus	355-361
11022403-4	2000	OUTCOME MEASURES: Modifications of the sensitivity of somatodendritic and postsynaptic 5-HT1A receptors using in vivo electrophysiological paradigms in animals treated with vehicle or (+/-)pindolol (20 mg/kg/day, subcutaneously) through osmotic minipumps for 2 weeks.	Pindolol	189-197	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-93
11022403-5	2000	RESULTS: (+/-)Pindolol attenuated the suppressant effect of the 5-HT autoreceptor agonist lysergic acid diethylamide (LSD) on the firing activity of 5-HT neurons, suggesting that (+/-)pindolol antagonized somatodendritic 5-HT1A autoreceptors in the dorsal raphe nucleus.	Pindolol	9-22	5-hydroxytryptamine receptor 1A	Rattus norvegicus	221-227
11022403-11	2000	Although pindolol is capable of antagonizing the 5-HT1A autoreceptor upon the initiation of a 5-HT reuptake-blocker treatment, it also induces a desensitization of this 5-HT1A autoreceptor, which could explain why patients do not relapse upon its discontinuation when they continue taking a 5-HT reuptake blocker.	Pindolol	9-17	5-hydroxytryptamine receptor 1A	Homo sapiens	49-55
11022403-11	2000	Although pindolol is capable of antagonizing the 5-HT1A autoreceptor upon the initiation of a 5-HT reuptake-blocker treatment, it also induces a desensitization of this 5-HT1A autoreceptor, which could explain why patients do not relapse upon its discontinuation when they continue taking a 5-HT reuptake blocker.	Pindolol	9-17	5-hydroxytryptamine receptor 1A	Homo sapiens	169-175
10942852-4	2000	We show that in healthy volunteers, in vivo, pindolol (n = 10) and penbutolol (n = 4), but not tertatolol (n = 4) occupy the human 5-HT(1A) receptors, at clinical doses.	Pindolol	45-53	5-hydroxytryptamine receptor 1A	Homo sapiens	131-138
10942852-5	2000	Pindolol, as well as the beta-blockers penbutolol and tertatolol, has high affinity for human 5-HT(1A) receptors in post-mortem brain slices (n = 4).	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	94-101
10942852-6	2000	Pindolol shows preference for 5-HT(1A) autoreceptors versus the post-synaptic receptors both in vitro and in vivo.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	30-37
10942852-7	2000	Our data reveal that pindolol doses used in antidepressant trials so far are suboptimal for significant occupancy at the 5-HT(1A) autoreceptor.	Pindolol	21-29	5-hydroxytryptamine receptor 1A	Homo sapiens	121-128
10942853-0	2000	Potentiation by (-)Pindolol of the activation of postsynaptic 5-HT(1A) receptors induced by venlafaxine.	Pindolol	19-27	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-69
10942853-11	2000	Taken together, these results indicate that (-)pindolol potentiated the activation of postsynaptic 5-HT(1A) receptors resulting from 5-HT reuptake inhibition probably by blocking the somatodendritic 5-HT(1A) autoreceptor, but not its postsynaptic congener.	Pindolol	47-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-106
10942853-11	2000	Taken together, these results indicate that (-)pindolol potentiated the activation of postsynaptic 5-HT(1A) receptors resulting from 5-HT reuptake inhibition probably by blocking the somatodendritic 5-HT(1A) autoreceptor, but not its postsynaptic congener.	Pindolol	47-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	199-206
11256582-6	2000	In addition, the 5-HTT gene polymorphisms were found to be associated with a better and faster response to SSRIs with or without pindolol augmentation in depressed patients.	Pindolol	129-137	solute carrier family 6 member 4	Homo sapiens	17-22
10962261-1	2000	Preclinical studies in rodents suggest that augmentation of serotonin reuptake inhibitors (SSRIs) therapy by the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor agent pindolol might reduce the delay between initiation of treatment and antidepressant response.	Pindolol	163-171	5-hydroxytryptamine receptor 1A	Homo sapiens	138-156
10962261-2	2000	This hypothesis is based on the ability of pindolol to potentiate the increase in serotonin (5-HT) transmission induced by SSRIs, an effect achieved by blockade of the 5-HT(1A) autoreceptors in the dorsal raphe nuclei (DRN).	Pindolol	43-51	5-hydroxytryptamine receptor 1A	Homo sapiens	168-175
10962261-4	2000	Here, we evaluated the occupancy of 5-HT(1A) receptors following treatment with controlled release pindolol in nine healthy volunteers with positron-emission tomography (PET).	Pindolol	99-107	5-hydroxytryptamine receptor 1A	Homo sapiens	36-43
10962261-12	2000	On the other hand, at each dose tested, pindolol occupancy of 5-HT(1A) receptors was higher in the DRN compared to cortical regions, demonstrating a significant in vivo selectivity for DRN 5-HT(1A) autoreceptors relative to cortico-limbic postsynaptic receptors.	Pindolol	40-48	5-hydroxytryptamine receptor 1A	Homo sapiens	62-69
10962261-12	2000	On the other hand, at each dose tested, pindolol occupancy of 5-HT(1A) receptors was higher in the DRN compared to cortical regions, demonstrating a significant in vivo selectivity for DRN 5-HT(1A) autoreceptors relative to cortico-limbic postsynaptic receptors.	Pindolol	40-48	5-hydroxytryptamine receptor 1A	Homo sapiens	189-196
10958120-0	2000	Partial 5-HT1A receptor agonist properties of (-)pindolol in combination with citalopram on serotonergic dorsal raphe cell firing in vivo.	Pindolol	49-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	8-14
10958120-2	2000	It has been postulated that pindolol enhances the antidepressant effect of SSRIs by blocking somatodendritic 5-HT1A autoreceptors, thus antagonizing the SSRI-induced feedback inhibition of midbrain 5-HT cell firing.	Pindolol	28-36	5-hydroxytryptamine receptor 1A	Rattus norvegicus	109-115
10958120-3	2000	A recent study, however, found that pindolol suppresses the firing rate of central 5-HT cells, suggesting that the compound possesses agonistic activity at 5-HT1A autoreceptors.	Pindolol	36-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	156-162
10958120-6	2000	RESULTS: Administration of 0.25 or 3.0 mg/kg (IV) (-)pindolol alone decreased the firing rate of a majority of the 5-HT cells studied, an effect that was reversed by the 5-HT1A receptor antagonist WAY 100635 (0.1 mg/kg, IV).	Pindolol	53-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	170-176
10958120-11	2000	CONCLUSIONS: The present findings support the previous notion that (-)pindolol possesses prominent agonistic activity at somatodendritic 5-HT1A autoreceptors, but also indicate that it may possess a weak antagonistic action at these receptors.	Pindolol	70-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	137-143
10862804-0	2000	5-HT(1A) agonist potential of pindolol: electrophysiologic studies in the dorsal raphe nucleus and hippocampus.	Pindolol	30-38	5-hydroxytryptamine receptor 1A	Homo sapiens	0-7
10862804-1	2000	BACKGROUND: The ability of pindolol to block 5-HT(1A) autoreceptors on serotonin-containing neurons in the raphe nuclei is thought to underlie the clinical reports of enhanced efficacy and rate of improvement in depressed patients treated with pindolol/selective serotonin reuptake inhibitor (SSRI) combinations.	Pindolol	27-35	5-hydroxytryptamine receptor 1A	Homo sapiens	45-52
10862804-1	2000	BACKGROUND: The ability of pindolol to block 5-HT(1A) autoreceptors on serotonin-containing neurons in the raphe nuclei is thought to underlie the clinical reports of enhanced efficacy and rate of improvement in depressed patients treated with pindolol/selective serotonin reuptake inhibitor (SSRI) combinations.	Pindolol	244-252	5-hydroxytryptamine receptor 1A	Homo sapiens	45-52
10862804-12	2000	The 5-HT(1A)-independent inhibition of hippocampal CA3 cell firing by pindolol suggests that this compound invokes multiple pharmacologic actions, all of which need to be assimilated into any proposed mechanism of action.	Pindolol	70-78	5-hydroxytryptamine receptor 1A	Homo sapiens	4-11
10862804-12	2000	The 5-HT(1A)-independent inhibition of hippocampal CA3 cell firing by pindolol suggests that this compound invokes multiple pharmacologic actions, all of which need to be assimilated into any proposed mechanism of action.	Pindolol	70-78	carbonic anhydrase 3	Homo sapiens	51-54
10864885-12	2000	Taken together it would therefore appear that although (+/-)pindolol alone has sufficient intrinsic activity to produce a desensitization of the 5-HT(1A) receptor, when given in combination with fluoxetine it is able to prevent the desensitization induced by not only fluoxetine but also itself.	Pindolol	55-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	145-152
11379796-5	2000	Clinical proof of this principal has been suggested in studies that found a significant augmenting effect when the beta-adrenergic/5-HT1A receptor antagonist, pindolol, was coadministered with SSRI treatment.	Pindolol	159-167	5-hydroxytryptamine receptor 1A	Homo sapiens	131-137
10864885-13	2000	This may suggest that the clinical augmentation of antidepressant action by pindolol, when co-administered with a SSRI, is via antagonism of the 5-HT(1A) receptor.	Pindolol	76-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	145-152
11062862-2	2000	Our present study has addressed the possibility that (+/-)-pindolol, which is a non-selective beta-adrenoceptor antagonist/somatodendritic 5-HT1A autoreceptor antagonist, might have the ability to enhance the level of extracellular 5-HT when used with selective serotonin reuptake inhibitor (SSRI; i.e., fluvoxamine).	Pindolol	53-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	139-145
11062862-9	2000	This indicates that (+/-)-pindolol has the ability to block the somatodendritic 5-HT1A autoreceptors, thereby weakening the fluvoxamine-induced indirect action of the autoreceptors in the raphe.	Pindolol	20-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	80-86
10823340-8	2000	On the other hand, infusion of 8-OHDPAT into the LDT selectively inhibits REMS, as does direct administration into the DRN of the 5-HT1A receptor antagonists pindolol or WAY 100635.	Pindolol	158-166	5-hydroxytryptamine receptor 1A	Homo sapiens	130-145
10727715-2	2000	This effect has been attributed to the antagonist effects of pindolol at the 5-HT(1A) receptor.	Pindolol	61-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	77-84
11379796-7	2000	We further discuss clinical studies that utilized pindolol as a test of this hypothesis in depressed patients and examine preclinical studies that challenge the notion that the beneficial effect of pindolol is due to functional antagonism of the 5-HT1A autoreceptors.	Pindolol	198-206	5-hydroxytryptamine receptor 1A	Homo sapiens	246-252
10720235-7	2000	As an example of the HPLC-ESI-MS analysis of the beta-blocker, pindolol, on a CN phase, the use of 90% acetonitrile in the mobile phase increased the ESI-MS signal by 790% when compared to a C18 phase which could use only 5% acetonitrile in the mobile phase for retention of the solute.	Pindolol	63-71	Bardet-Biedl syndrome 9	Homo sapiens	191-194
11185947-1	2000	OBJECTIVE: To critically review the literature on clinical trials in which pindolol, a 5HT1A receptor antagonist, has been used to augment the effects of antidepressants in patients with depression and to examine the pharmacodynamics and pharmacokinetics that may underlie such augmentations.	Pindolol	75-83	5-hydroxytryptamine receptor 1A	Homo sapiens	87-101
10649830-6	2000	Thus, the 5-HT1A receptor antagonists WAY 100635 and (-)-pindolol blocked the PA deficit by 8-OH-DPAT.	Pindolol	53-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-16
10649830-7	2000	The impairment of PA caused by PCA was attenuated by WAY 100635 and (-)-pindolol, suggesting an involvement of the 5-HT1A receptor.	Pindolol	68-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	115-121
10525755-3	1999	In humans, the growth hormone (GH) response to intravenous l-tryptophan (IV l-TRP) is blocked by the 5-HT(1A) antagonist pindolol and the prolactin response is blunted.	Pindolol	121-129	growth hormone 1	Homo sapiens	15-29
11041271-5	2000	[4] The (-)-pindolol/DOI-induced increase in forward locomotion could be antagonized by the beta1 adrenoceptor antagonist betaxolol (24 micromol kg(-1)).	Pindolol	8-20	adrenoceptor beta 1	Rattus norvegicus	92-110
10459173-0	1999	Displacement of the binding of 5-HT(1A) receptor ligands to pre- and postsynaptic receptors by (-)pindolol.	Pindolol	95-106	5-hydroxytryptamine receptor 1A	Homo sapiens	31-48
10459173-3	1999	3HCl] (WAY 100635) to 5-HT(1A) receptors by (-)pindolol in the brain of four different species, rat, guinea pig, monkey and human.	Pindolol	44-55	5-hydroxytryptamine receptor 1A	Homo sapiens	22-29
10459173-5	1999	The affinity of (-)pindolol for presynaptic 5-HT(1A) receptors in the dorsal raphe nucleus was similar to that observed in postsynaptic locations, such as hippocampus (areas CA1, CA3 and dentate gyrus) or entorhinal cortex.	Pindolol	19-27	5-hydroxytryptamine receptor 1A	Homo sapiens	44-51
10459173-9	1999	The affinity of (-)pindolol for human 5-HT(1A) receptors is below the mean plasma concentration attained in depressed patients treated with a combination of fluoxetine and pindolol, which indirectly supports an action of pindolol at 5-HT(1A) receptors in these patients.	Pindolol	19-27	5-hydroxytryptamine receptor 1A	Homo sapiens	38-45
10459173-9	1999	The affinity of (-)pindolol for human 5-HT(1A) receptors is below the mean plasma concentration attained in depressed patients treated with a combination of fluoxetine and pindolol, which indirectly supports an action of pindolol at 5-HT(1A) receptors in these patients.	Pindolol	19-27	5-hydroxytryptamine receptor 1A	Homo sapiens	233-240
10432475-1	1999	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	Pindolol	0-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
10432475-1	1999	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	Pindolol	0-12	5-hydroxytryptamine receptor 1B	Rattus norvegicus	63-69
10432475-4	1999	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.	Pindolol	78-90	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
10432475-5	1999	These data suggest that (-)-pindolol facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of beta 1/2-ARs and, to a lesser degree, by stimulation of 5-HT1A receptors, whereas 5-HT1B receptors are not involved.	Pindolol	24-36	5-hydroxytryptamine receptor 1A	Rattus norvegicus	190-196
10432475-8	1999	In conclusion, (-)-pindolol modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, 5-HT1A, and 5-HT1B receptors.	Pindolol	15-27	5-hydroxytryptamine receptor 1A	Rattus norvegicus	211-217
10432475-8	1999	In conclusion, (-)-pindolol modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, 5-HT1A, and 5-HT1B receptors.	Pindolol	15-27	5-hydroxytryptamine receptor 1B	Rattus norvegicus	223-229
10331108-1	1999	BACKGROUND: (+/-)Pindolol is a beta-adrenergic/5-HT1A receptor antagonist used in combination with certain antidepressant drugs to accelerate the onset of the antidepressive response.	Pindolol	12-25	5-hydroxytryptamine receptor 1A	Rattus norvegicus	47-53
10435400-0	1999	Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	20-26
10435400-7	1999	Two hours after pindolol administration, the regional 5-HT1A receptor occupancy was within the range 7-21% in the three subjects.	Pindolol	16-24	5-hydroxytryptamine receptor 1A	Homo sapiens	54-69
10435400-8	1999	The study confirms that the 5-HT1A-receptor may be a clinically significant target for pindolol.	Pindolol	87-95	5-hydroxytryptamine receptor 1A	Homo sapiens	28-43
10400249-2	1999	The present study assessed the effects of concomitant administration of fluoxetine and a 5-HT1A receptor antagonist, pindolol, on focal hippocampal (HIP) seizures elicited by electrical stimulation in rats.	Pindolol	117-125	5-hydroxytryptamine receptor 1A	Homo sapiens	89-104
10331108-11	1999	CONCLUSIONS: It is suggested that, at low doses, (+/-)pindolol acts as a somatodendritic 5-HT1A autoreceptor antagonist whereas at a higher dose, it decreases the tonic excitatory input from NA neurons to 5-HT neurons.	Pindolol	54-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	89-95
10100214-9	1999	[11C]NAD-299 binding was inhibited by addition of the 5-HT1A receptor ligands WAY-100635, pindolol, (+/-)-8-OH-DPAT, 5-HT, and buspirone, leaving a low background of nonspecific binding.	Pindolol	90-98	5-hydroxytryptamine receptor 1A	Homo sapiens	54-69
10369467-3	1999	Here we determined whether the beta-adrenoceptor/5-HT1A receptor ligands (+/-)-pindolol, (-)-tertatolol and (-)-penbutolol, interact with paroxetine in a similar manner.	Pindolol	73-87	5-hydroxytryptamine receptor 1A	Homo sapiens	49-64
10369467-19	1999	Indeed, the agonist action of (+/-)-pindolol at 5-HT1A autoreceptors probably explains its inability to enhance the effect of paroxetine on 5-HT in the frontal cortex.	Pindolol	30-44	5-hydroxytryptamine receptor 1A	Homo sapiens	48-54
16160947-4	1999	The hypothesis is supported by clinical data resulting from combining an SSRI with pindolol, which possesses 5-HT1A receptor antagonistic action.	Pindolol	83-91	5-hydroxytryptamine receptor 1A	Homo sapiens	109-124
9778659-4	1998	Although body temperature in humans remained unchanged following inhaled ergotamine, in the rat, subcutaneously injected ergotamine produced a hypothermia that was prevented by a pretreatment with the 5-HT1A/1B receptor/beta-adrenoceptor antagonist pindolol.	Pindolol	249-257	5-hydroxytryptamine receptor 1A	Homo sapiens	201-207
9928258-4	1998	That this adaptive change underlies, at least in part, the delayed therapeutic effect of SSRI in major depression is supported by the acceleration of the antidepressant response by the concomitant administration of the 5-HT1A autoreceptor antagonist pindolol with SSRIs.	Pindolol	250-258	5-hydroxytryptamine receptor 1A	Homo sapiens	219-225
9928287-0	1998	5-HT1A agonist activity of pindolol: reversal of the inhibitory effects on cell firing in the dorsal raphe nucleus but not in the hippocampus by WAY-100,635.	Pindolol	27-35	5-hydroxytryptamine receptor 1A	Homo sapiens	0-6
9873746-1	1998	Hybrid molecules built up by covalent coupling of aminopropanol derivatives (especially pindolol) with antidepressant drugs like fluoxetine, paroxetine or milnacipran were found to be potent and silent 5-HT1A antagonists (KB < 1 nM for 7c and 9a).	Pindolol	88-96	5-hydroxytryptamine receptor 1A	Homo sapiens	202-208
9881659-2	1998	The binding of pindolol to serum components increases proportionally with increasing alpha1-acid glycoprotein (AGP) concentration, indicating that AGP might play a major role in the binding of pindolol.	Pindolol	15-23	orosomucoid 1	Rattus norvegicus	85-109
9881659-2	1998	The binding of pindolol to serum components increases proportionally with increasing alpha1-acid glycoprotein (AGP) concentration, indicating that AGP might play a major role in the binding of pindolol.	Pindolol	15-23	orosomucoid 1	Rattus norvegicus	111-114
9881659-2	1998	The binding of pindolol to serum components increases proportionally with increasing alpha1-acid glycoprotein (AGP) concentration, indicating that AGP might play a major role in the binding of pindolol.	Pindolol	15-23	orosomucoid 1	Rattus norvegicus	147-150
9881659-2	1998	The binding of pindolol to serum components increases proportionally with increasing alpha1-acid glycoprotein (AGP) concentration, indicating that AGP might play a major role in the binding of pindolol.	Pindolol	193-201	orosomucoid 1	Rattus norvegicus	111-114
9881659-2	1998	The binding of pindolol to serum components increases proportionally with increasing alpha1-acid glycoprotein (AGP) concentration, indicating that AGP might play a major role in the binding of pindolol.	Pindolol	193-201	orosomucoid 1	Rattus norvegicus	147-150
9881659-6	1998	Good correlation was observed between the AUC of pindolol in rats and the AGP concentration in serum.	Pindolol	49-57	orosomucoid 1	Rattus norvegicus	74-77
9881659-8	1998	These results suggested that the influence of CAM on the pharmacokinetic properties of pindolol in CAM-treated rats can be explained by protein binding which, in turn, may be associated with variations in AGP concentration.	Pindolol	87-95	orosomucoid 1	Rattus norvegicus	205-208
9857976-4	1998	We tested the hypothesis that allelic variation of the 5-HTT promoter could be related to the antidepressant response to fluvoxamine and/or augmentation with pindolol (a serotonin autoreceptors antagonist) which has been suggested as an augmentation therapy for nonresponders.	Pindolol	158-166	solute carrier family 6 member 4	Homo sapiens	55-60
9778659-5	1998	Finally in humans, ergotamine did not alter prolactin or adrenocorticotropic hormone levels, but increased growth hormone level, which was prevented by pindolol.	Pindolol	152-160	growth hormone 1	Homo sapiens	107-121
9776347-12	1998	The aggravating effects of nicotine on myocardial ischaemia (CK release) as well as the expression of COX-2 mRNA were prevented by pretreatment with the beta-blocker pindolol (1 microM).	Pindolol	166-174	cytochrome c oxidase subunit II	Oryctolagus cuniculus	102-107
9566807-22	1998	The results of the present study suggest that pindolol is acting at presynaptic 5-HT1B serotonergic receptors, in addition to the 5-HT1A subtype, in augmenting the activity of antidepressants in the mouse forced swimming test.	Pindolol	46-54	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	80-86
9786516-4	1998	Intracisternal administration of the 5-HT1A receptor antagonists WAY-100635 (100 microg kg(-1)) and (-)pindolol (100 microg kg(-1)) significantly reduced the smoke-induced bradycardia, attenuated the pressor response and in the case of (-)pindolol, sympathetic nerve activity.	Pindolol	103-111	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	37-43
9786516-4	1998	Intracisternal administration of the 5-HT1A receptor antagonists WAY-100635 (100 microg kg(-1)) and (-)pindolol (100 microg kg(-1)) significantly reduced the smoke-induced bradycardia, attenuated the pressor response and in the case of (-)pindolol, sympathetic nerve activity.	Pindolol	239-247	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	37-43
9536453-0	1998	Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors.	Pindolol	37-45	5-hydroxytryptamine receptor 1A	Homo sapiens	81-87
9536453-1	1998	It has been proposed that the arylalkylamine, (-)pindolol, potentiates the therapeutic action of antidepressant drugs in humans by blockade of 5-HT1A autoreceptors.	Pindolol	46-57	5-hydroxytryptamine receptor 1A	Homo sapiens	143-149
9536453-3	1998	Herein, we demonstrate that (-)pindolol exhibits nanomolar affinity at human 5-HT1A receptors expressed in Chinese Hamster Ovary cells (CHO-h5-HT1A; Ki = 6.4 nmol/L).	Pindolol	31-39	5-hydroxytryptamine receptor 1A	Homo sapiens	77-83
9718263-3	1998	In this study, we investigate the effects of combining pindolol (2 mg/kg, s.c., bid) with the antidepressant paroxetine (2.5 mg/kg, i.p., bid) in the olfactory bulbectomised rat, an animal model of chronic (but not acute) antidepressant activity.	Pindolol	55-63	BH3 interacting domain death agonist	Rattus norvegicus	80-83
9920534-6	1998	An evaluation of the inhibitory activity of a series of 5-HT1A receptor antagonists produced the following rank order of potency; WAY100635 > LY206130 (IC50, 7.1 nM) > WAY100135 (30.8 nM) > pindolol (76.2 nM) > (-)UH-301 (92.8 nM).	Pindolol	199-207	5-hydroxytryptamine receptor 1A	Homo sapiens	56-71
9678651-5	1998	Pretreatment with a low dose of the 5-HT1A/beta-adrenoceptor antagonist (-)-pindolol (0.3 mg/kg, s.c.), 30 min prior to injection of alnespirone (0, 2, 5, and 10 mg/kg, i.p.)	Pindolol	72-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
9630361-0	1998	Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo.	Pindolol	53-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	92-98
9630361-4	1998	Here we investigated the actions of pindolol at the 5-HT1A autoreceptor by measuring its effect on 5-HT neuronal activity and release in the anaesthetized rat.	Pindolol	36-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	52-58
9630361-21	1998	We conclude that, under the experimental conditions used in this study, pindolol displays agonist effects at the 5-HT1A autoreceptor.	Pindolol	72-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	113-119
9630361-22	1998	These data are relevant to previous and ongoing clinical trials of pindolol in depression which are based on the rationale that the drug is an effective 5-HT1A autoreceptor antagonist.	Pindolol	67-75	5-hydroxytryptamine receptor 1A	Rattus norvegicus	153-159
9566807-22	1998	The results of the present study suggest that pindolol is acting at presynaptic 5-HT1B serotonergic receptors, in addition to the 5-HT1A subtype, in augmenting the activity of antidepressants in the mouse forced swimming test.	Pindolol	46-54	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	130-136
9553989-2	1998	The 5-HT2A/C receptor agonist DOI (0.025 1.6 mg kg-1, subcutaneously) produced a dose-dependent hyperthermia in rats, which was enhanced by addition of either of two 5-HT1A receptor antagonists, (-)-pindolol (0.5-1.0 mg kg-1, subcutaneously) or WAY-100,635 (0.1-0.4 mg kg-1, subcutaneously).	Pindolol	195-207	5-hydroxytryptamine receptor 2A	Rattus norvegicus	4-10
9570466-10	1998	In conclusion, these data suggest that when the firing activity of 5-HT neurons is normal in the presence of befloxatone, either after a two-day treatment together with (-)-pindolol or alone for 21 days, the tonic activation of postsynaptic 5-HT1A receptors is enhanced.	Pindolol	169-181	5-hydroxytryptamine receptor 1A	Rattus norvegicus	241-247
9504386-0	1998	Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain.	Pindolol	25-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	89-95
9504386-2	1998	The aim of the present work was to characterize the 5-hydroxytryptamine1A (5-HT1A) antagonistic actions of (-)-pindolol and WAY 100635 (N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl) cyclohexane carboxamide).	Pindolol	107-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-81
9504386-8	1998	(-)-Pindolol also prevented the 5-HT1A receptor-mediated hyperpolarization of CA1 pyramidal cells due to 5-HT (15 microM).	Pindolol	0-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
9504386-8	1998	(-)-Pindolol also prevented the 5-HT1A receptor-mediated hyperpolarization of CA1 pyramidal cells due to 5-HT (15 microM).	Pindolol	0-12	carbonic anhydrase 1	Rattus norvegicus	78-81
9504386-11	1998	In the hippocampus, (-)-pindolol completely prevented the hyperpolarization of CA1 pyramidal cells by 100 nM 5-CT (IC50=92 nM; apparent KB=20.1 nM), and of CA3 neurones by 300 nM 5-CT (IC50=522 nM; apparent KB= 115.1 nM).	Pindolol	20-32	carbonic anhydrase 1	Rattus norvegicus	79-82
9504386-11	1998	In the hippocampus, (-)-pindolol completely prevented the hyperpolarization of CA1 pyramidal cells by 100 nM 5-CT (IC50=92 nM; apparent KB=20.1 nM), and of CA3 neurones by 300 nM 5-CT (IC50=522 nM; apparent KB= 115.1 nM).	Pindolol	20-32	carbonic anhydrase 3	Rattus norvegicus	156-159
9300607-5	1997	These experimental results concur with clinical findings that 5-HT1A receptor antagonist pindolol potentiates the effect of 5-HT reuptake inhibitors.	Pindolol	89-97	5-hydroxytryptamine receptor 1A	Homo sapiens	62-77
9635544-3	1998	The agent pindolol, through its 5-HT1A receptor blocking property, has been shown to prevent the initial decrease in firing of rat 5-HT neurons associated with SSRI treatment.	Pindolol	10-18	5-hydroxytryptamine receptor 1A	Homo sapiens	32-38
9435184-6	1998	Further, 5-HT1A antagonists, NAN-190, penbutolol, (-)-pindolol, tertatolol and WAY-100635, produced dose-related decreases in 8-OH-DPAT-appropriate selection, and their potencies for antagonism in rats and pigeons were highly correlated (r = 0.96, P < .01).	Pindolol	50-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	9-15
9408806-1	1997	A double-blind study was undertaken to investigate the period of treatment with the beta-adrenoreceptor/5-hydroxytryptamine 1A (5-HT1A) antagonist pindolol required to enhance the antidepressant effects of paroxetine.	Pindolol	147-155	5-hydroxytryptamine receptor 1A	Homo sapiens	84-126
9408806-1	1997	A double-blind study was undertaken to investigate the period of treatment with the beta-adrenoreceptor/5-hydroxytryptamine 1A (5-HT1A) antagonist pindolol required to enhance the antidepressant effects of paroxetine.	Pindolol	147-155	5-hydroxytryptamine receptor 1A	Homo sapiens	128-134
9452183-6	1997	Pretreatment with (-)pindolol (5 mg/kg s.c.), a non-selective 5-HT1A subtype receptor antagonist, 30 min before imipramine 5 mg/kg, modified the effect of the antidepressant: an increase, instead of a decrease, on prefrontal cortex dialysate 5-HT was observed.	Pindolol	21-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-68
9384247-3	1997	The 5-HT1A receptor antagonists (-)-pindolol and LY 206130 (1-[1-H-indol-4-yloxy]-3-[cyclohexylamino]-2-propanol maleate) were examined in the present study and both enhanced the anticonvulsant action of fluoxetine in severe seizure GEPRs (GEPR-9s).	Pindolol	32-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9570466-3	1998	The combination of befloxatone and the 5-HT1A/1B receptor antagonist (-)-pindolol (15 mg/kg per day, s.c.) for 2 days slightly increased the firing activity of 5-HT neurons, whereas a treatment with (-)-pindolol alone for 2 days did not modify this parameter.	Pindolol	69-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
9570466-9	1998	In contrast, in rats treated with befloxatone in combination with (-)-pindolol for 2 days as well as with befloxatone alone for 21 days, WAY 100635 significantly increased the firing of CA3 pyramidal neurons.	Pindolol	66-78	carbonic anhydrase 3	Rattus norvegicus	186-189
9524980-5	1998	The results indicated that +/- pindolol decreases PRL concentrations depending on personality.	Pindolol	31-39	prolactin	Homo sapiens	50-53
9300623-7	1997	These data suggest that antagonist actions at 5-HT1A receptors (but not beta-adrenoceptors) are involved in the anxiolyticlike effects of (-)pindolol and pindobind 5-HT1A in the murine elevated plus-maze test.	Pindolol	138-149	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	46-52
9361334-5	1997	Blockade of the 5-HT1A receptors with pindolol (10 mg/kg) caused a strong reduction of the lower lip retraction induced both with mirtazapine and 8-OH-DPAT.	Pindolol	38-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	16-22
9335080-2	1997	We found that the 5-HT1A antagonists p-MPPI and pindolol caused CTA similar to that produced by LiCl.	Pindolol	48-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	18-24
9169295-2	1997	The partial 5-HT1A receptor agonist (-)-pindolol improved the performance in the low dose range (0.5-2.0 mg kg-1 s.c.), whereas a higher dose (8 mg kg-1) was ineffective.	Pindolol	36-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	12-18
9231743-8	1997	In addition, the antagonism of 5-HT1A autoreceptors by (-)-pindolol potentiates the action of milnacipran on both NA and 5-HT systems, without modifying the ratio of these activities.	Pindolol	55-67	5-hydroxytryptamine receptor 1A	Cavia porcellus	31-37
9241570-2	1997	Open studies suggest that, for selective serotonergic re-uptake inhibitor (SSRI) antidepressants, this latency may be reduced when the drug is taken with the 5HT1A receptor blocker pindolol.	Pindolol	181-189	5-hydroxytryptamine receptor 1A	Homo sapiens	158-172
9219866-0	1997	Human sleep EEG following the 5-HT1A antagonist pindolol: possible disinhibition of raphe neuron activity.	Pindolol	48-56	5-hydroxytryptamine receptor 1A	Homo sapiens	30-36
9219866-8	1997	The EEG power spectrum induced by pindolol tended to be opposite to what has previously been reported for ipsapirone, a 5-HT1A agonist.	Pindolol	34-42	5-hydroxytryptamine receptor 1A	Homo sapiens	120-126
9219866-9	1997	Therefore, the present data, tentatively, are consistent with the contention that pindolol inhibits, possibly selectively, somatodendritic 5-HT1A autoreceptors in humans and may antagonize self-inhibition of midbrain raphe nuclei 5-HT neurons.	Pindolol	82-90	5-hydroxytryptamine receptor 1A	Homo sapiens	139-145
9212275-3	1997	The inhibitory effects of 5HT and the 5HT1A agonist 8-OH-DPAT were shown to be antagonized by the 5HT1A antagonists spiperone and pindolol, respectively, indicating involvement of a 5HT1A receptor.	Pindolol	130-138	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-43
9212275-3	1997	The inhibitory effects of 5HT and the 5HT1A agonist 8-OH-DPAT were shown to be antagonized by the 5HT1A antagonists spiperone and pindolol, respectively, indicating involvement of a 5HT1A receptor.	Pindolol	130-138	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-103
9212275-3	1997	The inhibitory effects of 5HT and the 5HT1A agonist 8-OH-DPAT were shown to be antagonized by the 5HT1A antagonists spiperone and pindolol, respectively, indicating involvement of a 5HT1A receptor.	Pindolol	130-138	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-103
8922413-3	1996	This inward current was blocked by the 5-HT2 receptor antagonist ritanserin, whereas the IPSC depression was blocked by the 5-HT1B receptor antagonist pindolol.	Pindolol	151-159	5-hydroxytryptamine receptor 1B	Rattus norvegicus	124-130
9451712-3	1997	The effect of systemic administration of the 5-HT1A and 5-HT1B antagonist, (+/-)-pindolol (10 mg/kg), to increase 5-HT levels in hippocampus, was also not affected by chronic ECS.	Pindolol	75-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-62
9109104-1	1997	It has been reported that the 5-HT1A autoreceptor antagonist pindolol can accelerate the antidepressant response to the selective serotonin (5-HT) reuptake inhibitor (SSRI) paroxetine, presumably by preventing the initial decrease in firing activity of 5-HT neurons produced by the SSRI.	Pindolol	61-69	5-hydroxytryptamine receptor 1A	Homo sapiens	30-36
9109104-3	1997	The administration of the selective 5-HT1A agonist buspirone (20 mg/day for 1 week and 30 mg/day thereafter) with pindolol (2.5 mg TID) was used to activate selectively postsynaptic 5-HT1A receptors.	Pindolol	114-122	5-hydroxytryptamine receptor 1A	Homo sapiens	36-42
9109104-3	1997	The administration of the selective 5-HT1A agonist buspirone (20 mg/day for 1 week and 30 mg/day thereafter) with pindolol (2.5 mg TID) was used to activate selectively postsynaptic 5-HT1A receptors.	Pindolol	114-122	5-hydroxytryptamine receptor 1A	Homo sapiens	182-188
9225276-8	1997	Both cloned receptor subtypes displayed "5-HT1D receptor pharmacology" with the following rank order of binding affinities: 5-CT > 5-HT > sumatriptan > 8-OH-DPAT > (-)-pindolol.	Pindolol	176-188	5-hydroxytryptamine receptor 1D	Cavia porcellus	41-56
9037397-5	1997	The labeling of human 5-HT1A receptors with [3H]WAY-100635 was antagonised by the addition of 5-HT1A receptor ligands, 5-HT, buspirone, pindolol or 8-OH-DPAT (10 microM), leaving a very low background of non-specific binding.	Pindolol	136-144	5-hydroxytryptamine receptor 1A	Homo sapiens	22-28
9037397-5	1997	The labeling of human 5-HT1A receptors with [3H]WAY-100635 was antagonised by the addition of 5-HT1A receptor ligands, 5-HT, buspirone, pindolol or 8-OH-DPAT (10 microM), leaving a very low background of non-specific binding.	Pindolol	136-144	5-hydroxytryptamine receptor 1A	Homo sapiens	22-37
9503255-8	1997	+/- Pindolol antagonizes thermoregulatory and CD4+ cell responses.	Pindolol	4-12	CD4 molecule	Homo sapiens	46-49
9444561-2	1997	It was found that pretreatment with (-)-pindolol (2 mg kg-1 s.c.) potentiated the stereotyped forward locomotion induced by the 5-HT2A/C receptor agonist DOI (0.125-1.0 mg kg-1 s.c.) in rats observed in an open-field arena.	Pindolol	36-48	5-hydroxytryptamine receptor 2A	Rattus norvegicus	128-134
9444561-3	1997	This (-)-pindolol/DOI-induced stereotyped forward locomotion was fully antagonized by the 5-HT2A/C receptor antagonist ritanserin (2 mg kg-1 s.c.), suggesting that (-)-pindolol enhances serotonin release, resulting i.a.	Pindolol	5-17	5-hydroxytryptamine receptor 2A	Rattus norvegicus	90-96
9444561-3	1997	This (-)-pindolol/DOI-induced stereotyped forward locomotion was fully antagonized by the 5-HT2A/C receptor antagonist ritanserin (2 mg kg-1 s.c.), suggesting that (-)-pindolol enhances serotonin release, resulting i.a.	Pindolol	164-176	5-hydroxytryptamine receptor 2A	Rattus norvegicus	90-96
9444561-5	1997	This effect by (-)-pindolol is in all probability indirect since this compound lacks affinity for 5-HT2A/C receptors, and could be explained by reported antagonism of inhibitory serotonergic somato-dendritic 5-HT1A autoreceptors, although other possibilities related to 5-HT1B receptors or beta-adrenoceptors can not be excluded at this time.	Pindolol	15-27	5-hydroxytryptamine receptor 2A	Rattus norvegicus	98-104
9444561-5	1997	This effect by (-)-pindolol is in all probability indirect since this compound lacks affinity for 5-HT2A/C receptors, and could be explained by reported antagonism of inhibitory serotonergic somato-dendritic 5-HT1A autoreceptors, although other possibilities related to 5-HT1B receptors or beta-adrenoceptors can not be excluded at this time.	Pindolol	15-27	5-hydroxytryptamine receptor 1A	Rattus norvegicus	208-214
9444561-5	1997	This effect by (-)-pindolol is in all probability indirect since this compound lacks affinity for 5-HT2A/C receptors, and could be explained by reported antagonism of inhibitory serotonergic somato-dendritic 5-HT1A autoreceptors, although other possibilities related to 5-HT1B receptors or beta-adrenoceptors can not be excluded at this time.	Pindolol	15-27	5-hydroxytryptamine receptor 1B	Rattus norvegicus	270-276
8894179-3	1996	Several analogues of CYP and pindolol were synthesized that also produced antagonist effects at the beta 3-adrenoceptor.	Pindolol	29-37	adrenoceptor beta 3	Rattus norvegicus	100-119
8982661-9	1996	The in vivo ranking order of efficacy at 5-HT1A receptors was: WAY 100.635 = (-)-penbutolol < (-)-tertatolol < pindolol.	Pindolol	117-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	41-47
9064274-5	1996	On the other hand, beta-adrenoceptor blockers (e.g. [-]-pindolol, [-]-propranolol) have been shown to have antagonistic properties on the 5-HT1A receptor side.	Pindolol	52-64	5-hydroxytryptamine receptor 1A	Homo sapiens	138-153
8873352-5	1996	The treatment of patients with major depression using an SSRI and pindolol, a 5-HT1A/ beta-adrenoceptor antagonist, markedly reduced the latency of the antidepressant response in previously untreated patients and induced a rapid improvement in treatment-resistant patients.	Pindolol	66-74	5-hydroxytryptamine receptor 1A	Homo sapiens	78-84
8887989-0	1996	Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain.	Pindolol	10-18	5-hydroxytryptamine receptor 1A	Rattus norvegicus	60-66
8887989-8	1996	The inhibitory effect of LSD on 5-HT neuronal firing activity was also markedly attenuated in (-)pindolol-treated rats, indicating that somatodendritic 5-HT1A receptors were blocked by (-)pindolol.	Pindolol	97-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	152-158
8887989-8	1996	The inhibitory effect of LSD on 5-HT neuronal firing activity was also markedly attenuated in (-)pindolol-treated rats, indicating that somatodendritic 5-HT1A receptors were blocked by (-)pindolol.	Pindolol	188-196	5-hydroxytryptamine receptor 1A	Rattus norvegicus	152-158
8887989-9	1996	To determine whether (-)pindolol also blocked postsynaptic 5-HT1A receptors in hippocampus, 5-HT and the prototypical 5-HT1A agonist 8-OH-DPAT were applied by microiontophoresis onto CA3 pyramidal neurons following the same treatment.	Pindolol	24-32	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-65
8887989-11	1996	Taken together, these results indicate that (-)pindolol can potentiate the effects of an SSRI on extracellular 5-HT concentration by preventing the activation of somatodendritic 5-HT1A autoreceptors resulting from the blockade of the 5-HT transporter in the raphe.	Pindolol	47-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	178-184
8902886-5	1996	Pretreatment with pindolol, a 5-HT-1A antagonist, reduced the hypothermic response to 8-OH-DPAT, but pretreatment with ritanserin, a 5-HT-7 and 5-HT-2A/C antagonist, had no effect, confirming that the hypothermic response to 8-OH-DPAT is mediated predominantly by 5-HT-1A receptors.	Pindolol	18-26	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-37
8902886-5	1996	Pretreatment with pindolol, a 5-HT-1A antagonist, reduced the hypothermic response to 8-OH-DPAT, but pretreatment with ritanserin, a 5-HT-7 and 5-HT-2A/C antagonist, had no effect, confirming that the hypothermic response to 8-OH-DPAT is mediated predominantly by 5-HT-1A receptors.	Pindolol	18-26	5-hydroxytryptamine receptor 1A	Rattus norvegicus	264-271
8884690-5	1996	[125I]-Pindolol binding was sensitive to inhibition by ICI 118.551 (selective beta 2-adrenoceptor antagonist) but not to atenolol (selective beta 1-adrenoceptor antagonist), indicating receptors are predominantly of the beta 2-adrenoceptor subtype.	Pindolol	7-15	adrenoceptor beta 2	Rattus norvegicus	78-97
8884690-5	1996	[125I]-Pindolol binding was sensitive to inhibition by ICI 118.551 (selective beta 2-adrenoceptor antagonist) but not to atenolol (selective beta 1-adrenoceptor antagonist), indicating receptors are predominantly of the beta 2-adrenoceptor subtype.	Pindolol	7-15	adrenoceptor beta 2	Rattus norvegicus	220-239
8726963-0	1996	Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors.	Pindolol	89-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	120-126
8887982-7	1996	Our experiments using WAY 100635 and WAY 100135 provide clear evidence that NAN-190 and SDZ 216-525 act as agonists at the 5-HT1A autoreceptor, supporting our earlier studies using the non-selective 5-HT1A antagonist, pindolol.	Pindolol	218-226	5-hydroxytryptamine receptor 1A	Rattus norvegicus	123-129
8813565-5	1996	This effect of (-)-pindolol probably reflects its ability to block 5-HT1A autoreceptors, thereby abating the citalopram-induced indirect activation of these sites (secondary to the inhibition of 5-HT reuptake and elevation of extracellular 5-HT in the midbrain raphe).	Pindolol	15-27	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
8726963-4	1996	(-)-Pindolol, and antagonist at the somatodendritic 5-HT1A autoreceptor, dose-dependently (1, 3 and 5 mg/kg, s.c.) potentiated the fluoxetine dependent increase up to 458 percent of basal 5-HT levels for approximately 1.5 hours.	Pindolol	0-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	52-58
11725090-5	1996	The antagonist-binding pocket of the human 5-HT(1A)R is inferred from the interaction sites of pindolol with the receptor model: (1) the ionic interaction between the protonated amine of the ligand and the side chain of the conserved Asp-116, located in TMH 3; and (2) the hydrogen bonds between the ether oxygen and the hydroxyl group of the ligand and Asn-385, located in TMH 7.	Pindolol	95-103	5-hydroxytryptamine receptor 1A	Homo sapiens	43-50
8646418-2	1996	Pindolol, cyanopindolol (CYP) and iodocyanopindolol (IodoCYP) have been reported to act either as antagonists, agonists or partial agonists at the beta 3-adrenoceptor in different preparations.	Pindolol	0-8	adrenoceptor beta 3	Rattus norvegicus	147-166
8732312-2	1996	Addition of the 5-HT1A l beta-adrenergic antagonist pindolol did not alter OCD symptomatology but produced a rapid improvement of depressive symptoms.	Pindolol	52-60	5-hydroxytryptamine receptor 1A	Homo sapiens	16-22
8820175-5	1996	Racemic 8-OH-DPAT produced a dose-dependent hypothermia which was attenuated by the 5-HT1A antagonist pindolol, but not by the nonselective 5-HT antagonist methysergide.	Pindolol	102-110	5-hydroxytryptamine receptor 1A	Rattus norvegicus	84-90
8734491-7	1996	Although the antagonism of the 8-OH-DPAT-induced decrease of 5-HT levels by (-)-pindolol and (+/-)-tertatolol is likely to be related to their 5-HT1A antagonist properties, their ability to increase extracellular 5-HT levels when given alone may involve interactions with 5-HT1B receptors at hippocampal 5-HT terminals.	Pindolol	76-88	5-hydroxytryptamine receptor 1A	Rattus norvegicus	143-149
8734491-7	1996	Although the antagonism of the 8-OH-DPAT-induced decrease of 5-HT levels by (-)-pindolol and (+/-)-tertatolol is likely to be related to their 5-HT1A antagonist properties, their ability to increase extracellular 5-HT levels when given alone may involve interactions with 5-HT1B receptors at hippocampal 5-HT terminals.	Pindolol	76-88	5-hydroxytryptamine receptor 1B	Rattus norvegicus	272-278
8788488-7	1996	Pindolol significantly increased psychological responses to DMT, suggesting a buffering effect of 5-HT1A agonism on 5-HT2-mediated psychedelic effects.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	98-104
8838601-9	1996	We suggest that the inhibitory effects of propranolol and pindolol may involve interactions with 5-HT1A receptors in the CNS.	Pindolol	58-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	97-103
8838601-10	1996	Alternatively, it may be that the adverse effects of pindolol and propranolol are due to the simultaneous blockade of both beta 1- and beta 2-adrenoceptors.	Pindolol	53-61	adrenoceptor beta 1	Rattus norvegicus	123-155
8720579-3	1996	In support of receptor specificity, the effects of 8-OH-DPAT and DOI could be antagonised by pretreatment with the 5-HT1A/B and the 5-HT2A/C receptor antagonists (-)-pindolol (2 mg kg-1 s.c.) and ritanserin (2 mg kg-1 s.c.), respectively.	Pindolol	162-174	5-hydroxytryptamine receptor 2A	Rattus norvegicus	132-138
8688991-7	1996	Pindolol administration enhanced the decline of plasma ANP level after exercise (ANCOVA rep meas, pindolol vs placebo, p < 0.05).	Pindolol	0-8	natriuretic peptide A	Rattus norvegicus	55-58
8688991-7	1996	Pindolol administration enhanced the decline of plasma ANP level after exercise (ANCOVA rep meas, pindolol vs placebo, p < 0.05).	Pindolol	98-106	natriuretic peptide A	Rattus norvegicus	55-58
8688991-8	1996	Although pindolol increased the mean plasma VP level by 25% (ANCOVA rep meas for the increase, pindolol vs placebo, p < 0.05), drug effects on plasma VP-level were generally negligible.	Pindolol	9-17	arginine vasopressin	Rattus norvegicus	44-46
9026379-1	1996	Pindolol has been shown to be a partial agonist at 5-HT1A receptors in preclinical studies.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	51-57
9026379-5	1996	Pindolol significantly increased basal plasma cortisol concentrations, whereas it decreased plasma prolactin (PRL) concentrations and body temperature.	Pindolol	0-8	prolactin	Homo sapiens	99-108
9026379-5	1996	Pindolol significantly increased basal plasma cortisol concentrations, whereas it decreased plasma prolactin (PRL) concentrations and body temperature.	Pindolol	0-8	prolactin	Homo sapiens	110-113
9026379-6	1996	The increase in plasma cortisol due to pindolol suggests a 5-HT1A agonist action and is consistent with a 5-HT1A partial agonist mechanism in man whereas the PRL effects are consistent with an antagonist action at 5-HT1A receptors.	Pindolol	39-47	5-hydroxytryptamine receptor 1A	Homo sapiens	59-65
9026379-6	1996	The increase in plasma cortisol due to pindolol suggests a 5-HT1A agonist action and is consistent with a 5-HT1A partial agonist mechanism in man whereas the PRL effects are consistent with an antagonist action at 5-HT1A receptors.	Pindolol	39-47	5-hydroxytryptamine receptor 1A	Homo sapiens	106-112
9026379-6	1996	The increase in plasma cortisol due to pindolol suggests a 5-HT1A agonist action and is consistent with a 5-HT1A partial agonist mechanism in man whereas the PRL effects are consistent with an antagonist action at 5-HT1A receptors.	Pindolol	39-47	5-hydroxytryptamine receptor 1A	Homo sapiens	106-112
8786274-4	1995	The 5-HT1A/5-HT1B antagonist pindolol prevented the 5-carboxamidotryptamine-induced changes, whereas the 5-HT1A antagonist spiroxatrine and the 5-HT2 antagonists ketanserin and mianserin were ineffective.	Pindolol	29-37	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10
8734491-0	1996	(-)-pindolol and (+/-)-tertatolol affect rat hippocampal 5-HT levels through mechanisms involving not only 5-HT1A, but also 5-HT1B receptors.	Pindolol	0-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	107-113
8734491-0	1996	(-)-pindolol and (+/-)-tertatolol affect rat hippocampal 5-HT levels through mechanisms involving not only 5-HT1A, but also 5-HT1B receptors.	Pindolol	0-12	5-hydroxytryptamine receptor 1B	Rattus norvegicus	124-130
8786274-4	1995	The 5-HT1A/5-HT1B antagonist pindolol prevented the 5-carboxamidotryptamine-induced changes, whereas the 5-HT1A antagonist spiroxatrine and the 5-HT2 antagonists ketanserin and mianserin were ineffective.	Pindolol	29-37	5-hydroxytryptamine receptor 1B	Homo sapiens	11-17
8597527-5	1995	The growth hormone response to flesinoxan was blocked by pindolol but not by methysergide, whereas the prolactin response was blocked by methysergide but not by pindolol.	Pindolol	57-65	growth hormone 1	Homo sapiens	4-18
8564262-7	1995	Application of selective 5-HT1A receptor antagonists, (+/-)-pindolol or WAY-100635, attenuated the excitatory responses evoked by 5-HT.	Pindolol	54-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	25-31
8570029-12	1995	The flesinoxan-induced hypothermia was significantly attenuated by prior administration of the non-selective 5-HT1A antagonist pindolol and the 5-HT1/2 antagonist methysergide.	Pindolol	127-135	5-hydroxytryptamine receptor 1A	Rattus norvegicus	109-115
8788519-5	1996	In support of this hypothesis, pretreatment with (+/-)-pindolol or (+)-WAY100135, to block 5-HT1A autoreceptors, abolished the decrease in extracellular 5-HT produced by acute systemic injection of the reuptake blockers.	Pindolol	49-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	91-97
7495925-0	1995	Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men.	Pindolol	10-18	prolactin	Homo sapiens	70-79
8570772-1	1995	Previous reports from this laboratory have shown that pindolol, a partial serotonin1A receptor agonist, inhibited prolactin, but not cortisol secretion induced by administration of the serotonin (5-HT) precursor L-5-hydroxytryptophan or the direct-acting 5-HT2A/5HT2C receptor agonist MK-212.	Pindolol	54-62	5-hydroxytryptamine receptor 2A	Homo sapiens	255-261
7675967-2	1995	Pindolol pretreatment attenuated the (+)-fenfluramine-induced increase in prolactin concentrations but failed to affect the (+)-fenfluramine-induced cortisol increase.	Pindolol	0-8	prolactin	Homo sapiens	74-83
8532192-1	1995	The nonselective beta-adrenoceptor antagonists pindolol and cyanopindolol, which bind to 5-HT1A and 5-HT1A receptors showed an anticonflict effect by increasing the number of punished licks in the Vogel conflict test in rats, when administered directly into the CA, region of the dorsal hippocampus (i.hp.).	Pindolol	47-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	89-95
8532192-1	1995	The nonselective beta-adrenoceptor antagonists pindolol and cyanopindolol, which bind to 5-HT1A and 5-HT1A receptors showed an anticonflict effect by increasing the number of punished licks in the Vogel conflict test in rats, when administered directly into the CA, region of the dorsal hippocampus (i.hp.).	Pindolol	47-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	100-106
8532192-5	1995	The anticonflict effect of pindolol (1 microgram) was significantly reduced by (S)-WAY 100135, a selective 5-HT1A-receptor antagonist, administered i.hp (0.1 microgram) or s.c. (10 mg/kg).	Pindolol	27-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	107-113
8532192-10	1995	These results indicate that the anticonflict effect of the beta-blockers which were tested, or at least pindolol, depends on their agonist action on postsynaptic 5-HT1A receptors located in the hippocampus.	Pindolol	104-112	5-hydroxytryptamine receptor 1A	Rattus norvegicus	162-168
7566497-4	1995	The BMY7378- and 8-OH-DPAT-induced inhibition of 5-HT release were reversed by a 40 min pre-treatment with either (+/-)pindolol (8 mg/kg, s.c.) or WAY-100635 (0.3 mg/kg, s.c.), to block 5-HT1A autoreceptors.	Pindolol	114-127	5-hydroxytryptamine receptor 1A	Homo sapiens	186-192
7566497-7	1995	These data support the usefulness of pindolol, as well as the more specific compound WAY-100635, to block 5-HT1A autoreceptors.	Pindolol	37-45	5-hydroxytryptamine receptor 1A	Homo sapiens	106-112
7495925-4	1995	The MK-212-induced response in plasma cortisol was not diminished by pindolol pretreatment, whereas the MK-212-induced PRL response was significantly inhibited by pindolol pretreatment.	Pindolol	163-171	prolactin	Homo sapiens	119-122
7631902-4	1995	Microinjection of the nonselective 5-HT receptor antagonist methiothepin or the 5-HT1A/5-HT1B antagonist pindolol prevented any cardiovascular change by subsequent microinjection of 5-HT into the NTS.	Pindolol	105-113	5-hydroxytryptamine receptor 1A	Rattus norvegicus	80-86
7631902-4	1995	Microinjection of the nonselective 5-HT receptor antagonist methiothepin or the 5-HT1A/5-HT1B antagonist pindolol prevented any cardiovascular change by subsequent microinjection of 5-HT into the NTS.	Pindolol	105-113	5-hydroxytryptamine receptor 1B	Rattus norvegicus	87-93
7675949-3	1995	The effect of 8-OH-DPAT was blocked by the 5-HT1A receptor antagonists NAN 190, BMY 7378 and pindolol.	Pindolol	93-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
7647978-10	1995	The putative 5-HT1A receptor antagonist, pindolol, injected s.c. or i.c.v., significantly reduced the defaecation induced by systemically administered 8-OH-DPAT, buspirone or SR 57746A, but not 5-HT.	Pindolol	41-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
7712201-3	1995	Microinjections of spiperone and pindolol, 5-HT1A antagonists, into the RVLM inhibited the depressor response to 8-OH-DPAT intravenously injected or injected into the RVLM.	Pindolol	33-41	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
7568634-0	1995	Effect of pindolol on the prolactin response to d-fenfluramine.	Pindolol	10-18	prolactin	Homo sapiens	26-35
7568634-1	1995	We studied the effect of the 5-HT1A receptor antagonist, pindolol, on the prolactin (PRL) response to the 5-HT releasing agent, d-fenfluramine (d-FEN), in ten healthy male volunteers.	Pindolol	57-65	5-hydroxytryptamine receptor 1A	Homo sapiens	29-44
7568634-1	1995	We studied the effect of the 5-HT1A receptor antagonist, pindolol, on the prolactin (PRL) response to the 5-HT releasing agent, d-fenfluramine (d-FEN), in ten healthy male volunteers.	Pindolol	57-65	prolactin	Homo sapiens	74-83
7568634-1	1995	We studied the effect of the 5-HT1A receptor antagonist, pindolol, on the prolactin (PRL) response to the 5-HT releasing agent, d-fenfluramine (d-FEN), in ten healthy male volunteers.	Pindolol	57-65	prolactin	Homo sapiens	85-88
7568634-2	1995	Pindolol pretreatment lowered baseline PRL levels but, when this effect was taken into account, did not significantly attenuate the PRL response to d-FEN.	Pindolol	0-8	prolactin	Homo sapiens	39-42
7985599-3	1994	The hyperinsulinemic euglycemic clamp method showed that the significant decrease in insulin sensitivity (p < 0.01) induced by treatment with pindolol, propanolol, metoprolol, atenolol, or hydrochlorothiazide after 4 to 6 months persisted after 2 to 3 years of treatment.	Pindolol	145-153	insulin	Homo sapiens	9-16
7838138-2	1995	[3H]5-HT binding was performed in the presence of 100 nM pindolol, which is inactive at 5-ht7 receptors but prevents the binding of [3H]5-HT to 5-HT1A and 5-HT1B receptor binding sites.	Pindolol	57-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	144-161
7913223-1	1994	Using the conflict drinking test as a model, we studied in rats the effect of the nonselective beta-adrenoceptor blockers pindolol and cyanopindolol which bind to 5-HT1A and 5-HT1B receptors, and of the selective beta 1- and beta 2-adrenoceptor antagonists betaxolol and ICI 118,551, respectively, which have a negligible affinity for 5-HT receptors.	Pindolol	122-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	163-169
7936106-5	1994	The stereoselective antagonism by the pindolol enantiomers supports the proposal that 8-OH-DPAT-induced increase of waking and decrease of SWS depends on the activation of 5-HT1A receptors.	Pindolol	38-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	172-178
7855226-0	1994	Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man.	Pindolol	10-18	ribosomal protein L5	Homo sapiens	26-29
7855226-0	1994	Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man.	Pindolol	10-18	prolactin	Homo sapiens	61-70
7855226-4	1994	Pretreatment with pindolol, 30 mg orally, significantly inhibited the PRL but not the cortisol response to L-5-HTP, 200 mg PO.	Pindolol	18-26	prolactin	Homo sapiens	70-73
7855226-5	1994	Pindolol alone decreased basal plasma PRL levels and increased basal plasma cortisol levels, possibly due to 5-HT1A antagonist and agonists effects, respectively.	Pindolol	0-8	prolactin	Homo sapiens	38-41
7855226-5	1994	Pindolol alone decreased basal plasma PRL levels and increased basal plasma cortisol levels, possibly due to 5-HT1A antagonist and agonists effects, respectively.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	109-115
7921620-4	1994	The beta 3-agonists, bucindolol, CGP 12177A and pindolol exhibited the highest binding affinities; BRL 37344, LY 79771, ICI 201651 and SR 58611A presented high potencies in stimulating adenylyl cyclase; bupranolol appeared as the most efficient beta 3-antagonist.	Pindolol	48-56	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	4-10
7921620-4	1994	The beta 3-agonists, bucindolol, CGP 12177A and pindolol exhibited the highest binding affinities; BRL 37344, LY 79771, ICI 201651 and SR 58611A presented high potencies in stimulating adenylyl cyclase; bupranolol appeared as the most efficient beta 3-antagonist.	Pindolol	48-56	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	245-251
7945736-5	1994	The putative 5-HT1B agonist (m-trifluoromethyl-phenylpiperazine (TFMPP), but not [1-(3-chlorophenyl)piperazine] (m-CPP) or the 5-HT1B antagonists pindolol or quipazine, reduced the Bmax of cortical 5-HT1B sites (-16%).	Pindolol	146-154	5-hydroxytryptamine receptor 1B	Rattus norvegicus	13-19
7969811-4	1994	The 5-HT1A antagonists, (-)pindolol, (-)propranolol and spiperone, inhibited the effect of 8-OH-DPAT on wr-RSA.	Pindolol	27-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
7913223-4	1994	The anticonflict effects of pindolol and cyanopindolol were completely abolished by the 5-HT1A receptor and alpha 1-adrenoceptor antagonist 1-(2-methoxyphenyl)-4-[4-(2-phtalimmido)butyl]piperazine (NAN-190), but were not modified by the selective alpha 1(-)-adrenoceptor antagonist prazosin.	Pindolol	28-36	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
7913223-7	1994	Our results indicate that the anticonflict effects of pindolol and cyanopindolol depend on their agonist action on postsynaptic 5-HT1A receptors.	Pindolol	54-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-134
7984274-6	1994	In contrast, the non-selective 5-HT1A receptor antagonist (-)-pindolol (8 mg/kg s.c.) attenuated both SDZ 216,525 responses.	Pindolol	58-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
8208768-2	1994	This effect by 8-OH-DPAT was in turn completely antagonised by treatment with the new 5-HT1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(di-n-propylamino)tetralin [(S)-UH-301] (3.5 mg kg-1 SC), but not by the mixed 5-HT1 receptor/beta-adrenoceptor antagonist (-)pindolol (2.0 mg kg-1 SC).	Pindolol	264-272	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-92
7912102-0	1993	Extent of beta 1- and beta 2-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol, and propranolol in the elderly.	Pindolol	106-114	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	10-16
7984276-5	1994	Using [3H]5-HT, we found that the affinities of all the mutant receptors for propranolol and pindolol were significantly increased by 100-1000 fold, 5-HT1D alpha and 5-HT1F receptors showing the highest and the 5-HT1E receptor displaying the lowest affinity.	Pindolol	93-101	5-hydroxytryptamine receptor 1D	Homo sapiens	149-161
7984276-5	1994	Using [3H]5-HT, we found that the affinities of all the mutant receptors for propranolol and pindolol were significantly increased by 100-1000 fold, 5-HT1D alpha and 5-HT1F receptors showing the highest and the 5-HT1E receptor displaying the lowest affinity.	Pindolol	93-101	5-hydroxytryptamine receptor 1F	Homo sapiens	166-172
7984276-5	1994	Using [3H]5-HT, we found that the affinities of all the mutant receptors for propranolol and pindolol were significantly increased by 100-1000 fold, 5-HT1D alpha and 5-HT1F receptors showing the highest and the 5-HT1E receptor displaying the lowest affinity.	Pindolol	93-101	5-hydroxytryptamine receptor 1E	Homo sapiens	211-217
7912102-0	1993	Extent of beta 1- and beta 2-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol, and propranolol in the elderly.	Pindolol	106-114	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	22-28
7912102-5	1993	The results and conclusions were the following: (a) The extent to which metoprolol, pindolol, and propranolol occupied rabbit lung beta 1- and rat reticulocyte beta 2-adrenoceptors in plasma samples estimated accurately the intensity of beta-receptor antagonism in the patients who did not tolerate physiological and pharmacological tests measuring the degree of beta 1- and beta 2-adrenoceptor blockade.	Pindolol	84-92	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	131-137
7912102-5	1993	The results and conclusions were the following: (a) The extent to which metoprolol, pindolol, and propranolol occupied rabbit lung beta 1- and rat reticulocyte beta 2-adrenoceptors in plasma samples estimated accurately the intensity of beta-receptor antagonism in the patients who did not tolerate physiological and pharmacological tests measuring the degree of beta 1- and beta 2-adrenoceptor blockade.	Pindolol	84-92	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	160-166
7912102-6	1993	(b) The mean beta 1- and beta 2-receptor occupancy of pindolol and propranolol varied between 76% and 99% during the treatments.	Pindolol	54-62	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	13-19
7912102-6	1993	(b) The mean beta 1- and beta 2-receptor occupancy of pindolol and propranolol varied between 76% and 99% during the treatments.	Pindolol	54-62	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	25-31
7682614-6	1993	Spiperone, propranolol and pindolol (mixed 5-HT1A and 5-HT1B antagonists) effectively reversed both the tail-flick facilitation and the antagonistic effect on morphine sulfate-induced antinociception produced by 8-OH-DPAT and 5-CT.	Pindolol	27-35	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	43-49
7691622-7	1993	Pretreatment with the 5-HT1A receptor antagonist, (+/-)-pindolol (8 mg/kg, s.c.), abolished the FG5865 (0.3 mg/kg, s.c.)-induced reduction of 5-HT release, and (-)-pindolol (8 mg/kg, s.c.) similarly reversed the FG5893 (0.3 mg/kg, s.c.)-induced decrease.	Pindolol	50-64	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
7691622-7	1993	Pretreatment with the 5-HT1A receptor antagonist, (+/-)-pindolol (8 mg/kg, s.c.), abolished the FG5865 (0.3 mg/kg, s.c.)-induced reduction of 5-HT release, and (-)-pindolol (8 mg/kg, s.c.) similarly reversed the FG5893 (0.3 mg/kg, s.c.)-induced decrease.	Pindolol	160-172	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
8309968-2	1993	In a resident-intruder paradigm, (-)-pindolol (1.0-20.0 mg/kg), a beta-adrenergic 5-HT1A/1B antagonist, significantly attenuated all agonistic behaviors across the dose range employed.	Pindolol	33-45	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	82-88
8361577-3	1993	These responses were antagonised by the 5-HT1A antagonists (-)-propranolol and (-)-pindolol.	Pindolol	79-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
8361548-5	1993	By contrast, the selective 5-HT1B compound CP 93129 and (-)pindolol produced biphasic curves showing a majority of high affinity sites in the globus pallidus and the substantia nigra, whereas PAPP and sumatriptan (which are somewhat 5-HT1D selective) produced biphasic curves indicating a minority of high affinity sites in these areas.	Pindolol	59-67	5-hydroxytryptamine receptor 1B	Rattus norvegicus	27-33
8361548-5	1993	By contrast, the selective 5-HT1B compound CP 93129 and (-)pindolol produced biphasic curves showing a majority of high affinity sites in the globus pallidus and the substantia nigra, whereas PAPP and sumatriptan (which are somewhat 5-HT1D selective) produced biphasic curves indicating a minority of high affinity sites in these areas.	Pindolol	59-67	5-hydroxytryptamine receptor 1D	Rattus norvegicus	233-239
8361548-7	1993	The pharmacological profile of the major binding component was typical of the 5-HT1B type: 5-CT > CP 93129 > or = (-)pindolol > sumatriptan > or = PAPP > rauwolscine.	Pindolol	123-131	5-hydroxytryptamine receptor 1B	Rattus norvegicus	78-84
8361548-8	1993	The profile of the minor component of [125I]GTI binding is best characterised as that of a 5-HT1D site: 5-CT > PAPP > or = sumatriptan > rauwolscine > (-)pindolol > or = CP 93129.	Pindolol	166-174	5-hydroxytryptamine receptor 1D	Rattus norvegicus	91-97
7682614-6	1993	Spiperone, propranolol and pindolol (mixed 5-HT1A and 5-HT1B antagonists) effectively reversed both the tail-flick facilitation and the antagonistic effect on morphine sulfate-induced antinociception produced by 8-OH-DPAT and 5-CT.	Pindolol	27-35	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	54-60
8385783-8	1993	However, the results with [+/-]-pindolol, which has high affinity for the 5-HT1A receptor (34 nM) and negligible affinity for the alpha 2-adrenoceptor (24,600 nM), indicate that a significant component of yohimbine-induced stimulus control is mediated by the 5-HT1A receptor.	Pindolol	26-40	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-80
8471832-0	1993	Prolactin and thyrotropin responses to ECT after pindolol administration.	Pindolol	49-57	prolactin	Homo sapiens	0-9
8471832-2	1993	The effect of pindolol, a beta-receptor blocker with potent 5-HT1 receptor antagonistic properties, on the prolactin (PRL) and thyrotropin (TSH) responses to electroconvulsive therapy (ECT) was systematically studied in 12 female depressed patients.	Pindolol	14-22	prolactin	Homo sapiens	107-116
8436159-7	1993	Pindolol showed beta-adrenoceptor antagonistic effects in the supine position through decrements in heart rate from 70 to 66 beats.min-1 and LVEF from 0.57 to 0.52, and reduced mean arterial blood pressure from 103 mm Hg to 93 mm Hg.	Pindolol	0-8	CD59 molecule (CD59 blood group)	Homo sapiens	131-136
8095694-3	1993	Furthermore, beta-adrenergic antagonists such as propranolol and pindolol, which have been reported to be partial agonists or antagonists at the 5-HT1B receptors in other systems, were found to be full agonists.	Pindolol	65-73	5-hydroxytryptamine receptor 1B	Rattus norvegicus	145-151
8095694-8	1993	According to classical receptor theory these data indicate that pindolol is a partial agonist, relative to 5-HT, but because of the high density of 5-HT1B receptors in this system the difference between the intrinsic activities of the two drugs is masked.	Pindolol	64-72	5-hydroxytryptamine receptor 1B	Rattus norvegicus	148-154
1362454-1	1992	The aim of the study was to determine whether the antagonism with pindolol, mepindolol and bopindolol at the beta 1-adrenoceptor of the rat left atria, a tissue with plenty of spare beta 1-adrenoceptors for isoprenaline maximum responses, was readily reversible or not.	Pindolol	66-74	adrenoceptor beta 1	Rattus norvegicus	109-128
1369587-5	1992	(+/-)-Pindolol, known to have 5-HT1A antagonist properties, blocked the effect induced by an optimal dose of 8-OH-DPAT after injection into the PVN.	Pindolol	0-14	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
1369587-6	1992	This same dose of 8-OH-DPAT also induced a decrease of hypothalamic CRH concentration, which was completely antagonized as well by pretreatment injection of (+/-)-pindolol into the PVN.	Pindolol	157-171	corticotropin releasing hormone	Rattus norvegicus	68-71
1359573-2	1992	In contrast, another partial 5-HT1A agonist, pindolol (10 mg/kg), slightly but significantly depressed body temperature by itself but did not attenuate hypothermia elicited by 8-OH-DPAT.	Pindolol	45-53	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	29-35
1568034-2	1992	Pressor responses to angiotensin II and to phenylephrine were markedly decreased prior to treatment and were improved by administration of indomethacin, dextran, KCl, captopril, propranolol or pindolol.	Pindolol	193-201	angiotensinogen	Homo sapiens	21-35
1366265-7	1992	The insulin sensitivity index was decreased by 34% during propranolol treatment and by 17% during pindolol treatment.	Pindolol	98-106	insulin	Homo sapiens	4-11
1316283-5	1992	The phase advance induced by 8-OH-DPAT was blocked by pretreatment with (-)-pindolol, a 5-HT1A receptor antagonist.	Pindolol	72-84	5-hydroxytryptamine receptor 1A	Homo sapiens	88-103
1349154-1	1992	The 5-hydroxytryptamine1A (5-HT1A) receptor can bind certain beta-adrenergic receptor antagonists, such as pindolol, with high affinity.	Pindolol	107-115	5-hydroxytryptamine receptor 1A	Homo sapiens	4-25
1349154-1	1992	The 5-hydroxytryptamine1A (5-HT1A) receptor can bind certain beta-adrenergic receptor antagonists, such as pindolol, with high affinity.	Pindolol	107-115	5-hydroxytryptamine receptor 1A	Homo sapiens	27-43
1309479-7	1992	The beta 1 and beta 2 antagonists pindolol, oxprenolol, and CGP12177 are agonists of the beta 3AR.	Pindolol	34-42	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	4-21
1309479-7	1992	The beta 1 and beta 2 antagonists pindolol, oxprenolol, and CGP12177 are agonists of the beta 3AR.	Pindolol	34-42	adrenoceptor beta 3	Homo sapiens	89-97
1641195-2	1992	The binding of 3H-5-HT was limited to 5-HT1D sites (5-CT-sensitive) by co-incubating pindolol and mesulergine with [3H]5-HT, and by using 10 microM 5-HT to determine non-specific binding.	Pindolol	85-93	5-hydroxytryptamine receptor 1D	Homo sapiens	38-44
1310718-0	1992	Down-regulation of beta-adrenergic receptors by pindolol in Gs alpha-transfected S49 cyc- murine lymphoma cells.	Pindolol	48-56	GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus	Mus musculus	60-68
1310718-0	1992	Down-regulation of beta-adrenergic receptors by pindolol in Gs alpha-transfected S49 cyc- murine lymphoma cells.	Pindolol	48-56	peptidylprolyl isomerase A, pseudogene 1	Mus musculus	85-89
1310718-1	1992	The role of the alpha subunit of the guanine nucleotide-binding regulatory protein that stimulates adenylyl cyclase (GS alpha) in the down-regulation of beta-adrenergic receptors by pindolol was studied in S49 cyc- cells (normally GS alpha-deficient) transfected to express functional recombinant rat GS alpha.	Pindolol	182-190	GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus	Mus musculus	117-125
1310718-9	1992	When cells were grown in the presence of dexamethasone, exposure to 50 nM pindolol for 12 h down-regulated the density of beta-adrenergic receptors in S49 WT cells to 60% of that in cells grown in the absence of pindolol, but pindolol had no effect on the density of receptors on cyc- or GS alpha IND cells.	Pindolol	74-82	peptidylprolyl isomerase A, pseudogene 1	Mus musculus	280-284
1310718-9	1992	When cells were grown in the presence of dexamethasone, exposure to 50 nM pindolol for 12 h down-regulated the density of beta-adrenergic receptors in S49 WT cells to 60% of that in cells grown in the absence of pindolol, but pindolol had no effect on the density of receptors on cyc- or GS alpha IND cells.	Pindolol	74-82	GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus	Mus musculus	288-296
1310718-10	1992	When GS alpha CST cells were exposed to 50 nM pindolol for 12 h, the density of beta-adrenergic receptors was down-regulated by the same amount as in S49 WT cells.	Pindolol	46-54	GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus	Mus musculus	5-13
1310718-11	1992	These results suggest that GS alpha is necessary to restore the ability of pindolol to down-regulate beta-adrenergic receptors in S49 cyc- cells and that the protein must be expressed at a level comparable to that found in S49 WT cells.	Pindolol	75-83	GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus	Mus musculus	27-35
1310718-11	1992	These results suggest that GS alpha is necessary to restore the ability of pindolol to down-regulate beta-adrenergic receptors in S49 cyc- cells and that the protein must be expressed at a level comparable to that found in S49 WT cells.	Pindolol	75-83	peptidylprolyl isomerase A, pseudogene 1	Mus musculus	134-138
1310232-5	1992	During normoxia, isoproterenol and pindolol significantly decreased PVR by 17.5 and 6.7% (P less than 0.01), respectively, but propranolol had no effect on PVR.	Pindolol	35-43	PVR cell adhesion molecule	Canis lupus familiaris	68-71
1570392-1	1992	Ten healthy subjects received buspirone (30 mg orally) with and without pre-treatment with the 5-HT1A receptor antagonist, pindolol (80 mg over 3 days).	Pindolol	123-131	5-hydroxytryptamine receptor 1A	Homo sapiens	95-110
1570392-2	1992	Following pindolol treatment the growth hormone and hypothermic responses to buspirone were significantly decreased.	Pindolol	10-18	growth hormone 1	Homo sapiens	33-47
1670741-4	1991	Following propranolol and pindolol, resting acceleration fell by 4.5 and 2 m/sec2, respectively p less than 0.05.	Pindolol	26-34	fucosyltransferase 2	Homo sapiens	77-81
1673069-9	1991	Microinjections of the non-selective 5-HT1A receptor antagonists, (+/-)-pindolol (2.7 nmol) or methiothepin (5.2 nmol), into the raphe obscurus prevented the increase in blood pressure caused by microinjection of flesinoxan.	Pindolol	66-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
1686311-3	1991	The induction of IL-1 beta mRNA was blocked by intraperitoneal pretreatment with beta-blockers propranolol (0.1-1 mg/kg, but not 0.01 mg/kg) and pindolol (0.3 and 1 mg/kg).	Pindolol	145-153	interleukin 1 beta	Rattus norvegicus	17-26
1980200-15	1990	Pindolol may produce this effect, which was not seen with xamoterol, because of its specific beta 2-adrenoceptor partial agonist activity.	Pindolol	0-8	adrenoceptor beta 2	Homo sapiens	93-112
2006240-0	1991	Pindolol decreases prolactin and growth hormone responses to intravenous L-tryptophan.	Pindolol	0-8	prolactin	Homo sapiens	19-28
2006240-0	1991	Pindolol decreases prolactin and growth hormone responses to intravenous L-tryptophan.	Pindolol	0-8	growth hormone 1	Homo sapiens	33-47
2006240-2	1991	Pindolol pretreatment (40 mg over 48 h) markedly attenuated the GH response to LTP and modestly, but significantly, reduced the LTP-induced increase in plasma PRL.	Pindolol	0-8	prolactin	Homo sapiens	159-162
1964908-2	1990	MDL 73005EF dose dependently decreased the hippocampal 5-HT output measured by in vivo microdialysis in chloral hydrate-anaesthetised rats and this response was antagonised by the 5-HT1A/B receptor antagonist, pindolol.	Pindolol	210-218	5-hydroxytryptamine receptor 1A	Rattus norvegicus	180-186
1964908-4	1990	MDL 73005EF failed to alter basal plasma adrenocorticotropin (ACTH) levels but, in common with pindolol, attenuated the ACTH response to the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	Pindolol	95-103	5-hydroxytryptamine receptor 1A	Rattus norvegicus	141-147
1829235-7	1991	The fact that the 5-HT1A agonist 8-OH-DPAT produced a decrease in core temperature, together with the observation that administration of the 5-HT1 antagonist (-)pindolol antagonized the 5-HT as well as the 8-OH-DPAT-induced decrease, indicates the involvement of DR 5-HT1A receptors in rat thermoregulation.	Pindolol	161-169	5-hydroxytryptamine receptor 1A	Rattus norvegicus	266-272
1970503-6	1990	The beta 1- and beta 2-adrenoceptor affinity (-log equilibrium dissociation constant) of the enantiomers was determined from competition binding experiments (radioligand: [125I]-(S)-pindolol) performed in membranes prepared from the guinea-pig left ventricular free wall (predominantly beta 1) and soleus muscle (beta 2).	Pindolol	178-190	beta-2 adrenergic receptor	Cavia porcellus	4-35
2222510-8	1990	This inhibitory response was used to determine the pharmacological characteristics of drugs that reportedly have high affinity for 5-HT1A binding sites, such as 1-[2-(4-aminophenyl)ethyl]-4-(3-trifluoromethylphenyl)piperazine (PAPP) and (-)pindolol.	Pindolol	237-248	5-hydroxytryptamine receptor 1A	Rattus norvegicus	131-137
2222510-11	1990	Because of the low intrinsic activity of (-)pindolol, it was tested as an antagonist of the inhibition produced by 5-HT1A receptor agonists in rat hippocampal membranes.	Pindolol	41-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	115-121
1700204-6	1990	Treatment with ICI 118,551 completely eliminated the 45% increase in plasma NE elicited by 100 micrograms/kg of pindolol even though the decrease in MAP caused by this dose of pindolol was the same in the presence (-33 mm Hg) and absence (-34 mm Hg) of beta 2-adrenoceptor blockade.	Pindolol	112-120	adrenoceptor beta 2	Rattus norvegicus	253-272
2259248-5	1990	The inhibitory action of 8-OH-DPAT and several other selective 5-HT1A receptor active drugs on 5-HT release is sensitive to pindolol, further supporting the idea that the 5-HT receptor being measured is of the 5-HT1 subtype.	Pindolol	124-132	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
1977731-9	1990	We conclude that the effects of pindolol on the plasma lipid profile are due to its ISA and that the process activated (possibly plasma lecithin-cholesterol acyltransferase activity) is under minimal sympathetic control and, therefore, sensitive to the expression of ISA both at rest and in response to exercise.	Pindolol	32-40	lecithin-cholesterol acyltransferase	Homo sapiens	136-172
2148726-6	1990	Pindolol, spiperone, spiroxatrine and NAN-190 all have a high affinity for the 5-HT1A receptor.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Rattus norvegicus	79-85
2175014-0	1990	Effects of chronic pindolol treatment on human myocardial beta 1- and beta 2-adrenoceptor function.	Pindolol	19-27	adrenoceptor beta 2	Homo sapiens	70-89
2123971-5	1990	The putative 5-HT1A antagonist, (+/-) pindolol, attenuated the reversal of catalepsy by 8-OHDPAT.	Pindolol	32-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
1977175-9	1990	It was suggested that the strongly inhibitory effects of propranolol and pindolol on male rat sex behavior may well be due to their 5-HT1A antagonistic binding properties rather than their beta-antagonistic properties.	Pindolol	73-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	132-138
1972064-5	1990	In contrast, the reduction in pressure which occurs with a beta blocker possessing a high degree of ISA, such as pindolol, is associated with a reduction in total peripheral resistance and little change in cardiac output.	Pindolol	113-121	amyloid beta precursor protein	Homo sapiens	57-63
1694913-5	1990	Pindolol significantly decreased total C, HDL-C, and HDL2-C levels in males.	Pindolol	0-8	junctophilin 3	Homo sapiens	53-57
1970616-6	1990	Prior administration of (-)pindolol, a beta-adrenoceptor antagonist that blocks 5-HT1A receptors, markedly diminished the rise in plasma adrenaline levels and abolished the hyperglycemia triggered by 8-OH-DPAT.	Pindolol	24-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	80-86
2138331-5	1990	Furthermore, pretreatment with a partial 5-HT1A agonist (+/-)pindolol blocked the inhibitory effects of 8-OH-DPAT to the level of inhibition produced by (+/-)pindolol itself.	Pindolol	153-166	5-hydroxytryptamine receptor 1A	Rattus norvegicus	41-47
2354485-6	1990	Lipoprotein lipase activity in heparin-treated plasma was significantly higher after pindolol administration.	Pindolol	85-93	lipoprotein lipase	Homo sapiens	0-18
2354485-7	1990	The results suggest that the reduction in triglyceride levels and increase in HDL-C after pindolol are partly a response to an increase in the hydrolysis of VLDL resulting from an increase in lipoprotein lipase activity.	Pindolol	90-98	lipoprotein lipase	Homo sapiens	192-210
1968468-5	1990	The nonselective beta-adrenergic and selective 5-HT1A/1B receptor antagonist (+/-)pindolol was without effect on basal HPA activity, but completely antagonized the IPS-induced plasma ACTH and cortisol responses.	Pindolol	77-90	5-hydroxytryptamine receptor 1A	Homo sapiens	47-53
1968468-5	1990	The nonselective beta-adrenergic and selective 5-HT1A/1B receptor antagonist (+/-)pindolol was without effect on basal HPA activity, but completely antagonized the IPS-induced plasma ACTH and cortisol responses.	Pindolol	77-90	proopiomelanocortin	Homo sapiens	183-187
1692973-7	1990	Pretreatment with (-)pindolol (8 mg/kg s.c.), which has high affinity for 5-HT1A radioligand binding sites, blocked the reduction of hippocampal 5-HT release induced by a submaximally effective dose of (+)ALK-3.	Pindolol	21-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-80
1692973-7	1990	Pretreatment with (-)pindolol (8 mg/kg s.c.), which has high affinity for 5-HT1A radioligand binding sites, blocked the reduction of hippocampal 5-HT release induced by a submaximally effective dose of (+)ALK-3.	Pindolol	21-29	bone morphogenetic protein receptor type 1A	Rattus norvegicus	205-210
2252308-7	1990	Rat 5-HT1B receptors recognize with high affinity a number of beta-adrenoceptor antagonists, such as SDZ 21-009, cyanopindolol, pindolol, propranolol and isamoltane.	Pindolol	118-126	5-hydroxytryptamine receptor 1B	Rattus norvegicus	4-10
2101330-0	1990	Inhibition of chlorpromazine-induced catalepsy by the 5-HT-1A ligands pindolol and buspirone in mice.	Pindolol	70-78	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	54-61
1969119-4	1990	The effects of 8-OH-DPAT and SM-3997 on the hippocampal RSA were blocked by pindolol, which has 5-HT1A antagonistic activity.	Pindolol	76-84	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	96-102
2138331-5	1990	Furthermore, pretreatment with a partial 5-HT1A agonist (+/-)pindolol blocked the inhibitory effects of 8-OH-DPAT to the level of inhibition produced by (+/-)pindolol itself.	Pindolol	56-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	41-47
2533557-4	1989	In this respect, (+)ALK-3 was significantly less efficacious although its behavioural action was prevented by pindolol (8 mg/kg s.c.), indicating that it was 5-HT1A receptor mediated.	Pindolol	110-118	bone morphogenetic protein receptor type 1A	Rattus norvegicus	20-25
2274641-4	1990	Pretreatment with the nonselective beta-adrenergic/5-HT1-like antagonist, pindolol suppressed the maximal PRL response to buspirone challenge depending upon dose (i.e., between 49 to 90% suppression at best dose).	Pindolol	74-82	prolactin	Homo sapiens	106-109
8082505-5	1994	The serotonin 5HT1A agonist 8-OH-DPAT dramatically and dose-dependently increased the frequency of long-duration, high-amplitude waves in the transverse and distal colon, and concurrently promoted defecation; these effects were prevented by the putative 5HT1A antagonist pindolol.	Pindolol	271-279	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-19
8082505-5	1994	The serotonin 5HT1A agonist 8-OH-DPAT dramatically and dose-dependently increased the frequency of long-duration, high-amplitude waves in the transverse and distal colon, and concurrently promoted defecation; these effects were prevented by the putative 5HT1A antagonist pindolol.	Pindolol	271-279	5-hydroxytryptamine receptor 1A	Rattus norvegicus	254-259
2576226-1	1989	The mixed beta-adrenoceptor and 5-HT1A receptor antagonists, (-)-pindolol and propranolol, enhance rather than inhibit the hyperlocomotion induced in rats by the 5-HT1A receptor agonist, 8-OH-DPAT.	Pindolol	61-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
2576226-1	1989	The mixed beta-adrenoceptor and 5-HT1A receptor antagonists, (-)-pindolol and propranolol, enhance rather than inhibit the hyperlocomotion induced in rats by the 5-HT1A receptor agonist, 8-OH-DPAT.	Pindolol	61-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	162-168
2576226-7	1989	(-)-Pindolol (1 mg/kg) also enhanced the locomotion induced by the putative selective 5-HT1A receptor partial agonists, flesinoxan and ipsapirone, but not that induced by 5-OH-DPAT, a DA2 receptor agonist.	Pindolol	0-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-92
1980461-2	1990	The response was attenuated by the nonselective 5-HT1/2 receptor antagonist metergoline and was completely antagonized by the nonselective beta-adrenoceptor antagonist pindolol, which interacts stereoselectively with the 5-HT1A receptor.	Pindolol	168-176	5-hydroxytryptamine receptor 1A	Homo sapiens	221-236
34128161-5	2021	Moreover, the addition of cyclodextrins (HP-beta-CD and beta-CD) in aqueous media enhanced the fluorescence of pindolol.	Pindolol	111-119	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	44-51
34128161-5	2021	Moreover, the addition of cyclodextrins (HP-beta-CD and beta-CD) in aqueous media enhanced the fluorescence of pindolol.	Pindolol	111-119	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	56-63
2664084-2	1989	Two binding sites were detected in the presence of 1 microM pindolol (to block 5-HT1A and 5-HT1B receptors), and 100 nM mesulergine (to block 5-HT1C and 5-HT2 receptors).	Pindolol	60-68	5-hydroxytryptamine receptor 1A	Homo sapiens	79-85
2572975-3	1989	Special attention was paid to the effects of drugs known to bind with high affinity to 5-HT1B (pindolol, propranolol, cyanopindolol, SDZ 21-009, isamoltane) or 5-HT1D recognition sites (yohimbine, rauwolscine).	Pindolol	95-103	5-hydroxytryptamine receptor 1B	Rattus norvegicus	87-93
2527473-0	1989	Effects of propranolol and pindolol on plasma ANP levels in humans at rest and during exercise.	Pindolol	27-35	natriuretic peptide A	Homo sapiens	46-49
2664084-2	1989	Two binding sites were detected in the presence of 1 microM pindolol (to block 5-HT1A and 5-HT1B receptors), and 100 nM mesulergine (to block 5-HT1C and 5-HT2 receptors).	Pindolol	60-68	5-hydroxytryptamine receptor 1B	Homo sapiens	90-96
2530590-3	1989	The corticosterone response to 8-OH-DPAT was also antagonized by spiperone, (+/-)- and (-)-pindolol and (+/-)-propranolol, all of which have been shown to have a high affinity for 5-HT1A receptors, though in most cases no complete blockade was found.	Pindolol	87-99	5-hydroxytryptamine receptor 1A	Rattus norvegicus	180-186
2573966-3	1989	Alberto Kaumann suggests that such non-conventional partial agonists, often analogues of pindolol, may act through a third heart beta-adrenoceptor, which resembles the beta 3-adrenoceptor of white adipocytes and smooth muscle of airways and ileum.	Pindolol	89-97	adrenoceptor beta 3	Homo sapiens	168-187
2554837-6	1989	It appears an exercise-induced increase in plasma ANF which was more elevated in subjects treated with pindolol, but which had no inhibitory effect on ALD secretion in theses conditions.	Pindolol	103-111	natriuretic peptide A	Homo sapiens	50-53
2527226-4	1989	During sea-level exercise, pindolol caused a reduction in plasma renin activity (PRA, 2.83 +/- 0.35 vs. 5.13 +/- 0.7 ng ANG I.ml-1.h-1, P less than 0.01), an increase in plasma alpha-atrial natriuretic factor (alpha-ANF) level (23.1 +/- 2.9 (P) vs. 10.4 +/- 1.5 (C) pmol/1, P less than 0.01), and no change in plasma aldosterone concentration [0.50 +/- 0.04 (P) vs. 0.53 +/- 0.03 (C) nmol/1].	Pindolol	27-35	renin	Homo sapiens	65-70
2527226-4	1989	During sea-level exercise, pindolol caused a reduction in plasma renin activity (PRA, 2.83 +/- 0.35 vs. 5.13 +/- 0.7 ng ANG I.ml-1.h-1, P less than 0.01), an increase in plasma alpha-atrial natriuretic factor (alpha-ANF) level (23.1 +/- 2.9 (P) vs. 10.4 +/- 1.5 (C) pmol/1, P less than 0.01), and no change in plasma aldosterone concentration [0.50 +/- 0.04 (P) vs. 0.53 +/- 0.03 (C) nmol/1].	Pindolol	27-35	angiotensinogen	Homo sapiens	120-125
2907348-5	1988	Moreover, in the pindolol group lymphocyte beta 2-adrenoceptor density was decreased.	Pindolol	17-25	adrenoceptor beta 2	Homo sapiens	43-62
2736568-3	1989	Apo A-II levels were increased significantly and the apo B/apo A-I ratio, which is one of the atherogenic indexes, was decreased significantly after pindolol therapy.	Pindolol	149-157	apolipoprotein A2	Homo sapiens	0-8
2651861-9	1989	A beta blocker induced sinus bradycardia consistently improved with change of treatment to carteolol and pindolol.	Pindolol	105-113	amyloid beta precursor protein	Homo sapiens	0-6
2663749-1	1989	The response of two ophthalmic betablockers, Timolol (without ISA) and Pindolol (with marked ISA), on IOP and tonographic outflow facility was investigated in a single-blind clinical study on 20 patients with glaucoma or ocular hypertension.	Pindolol	71-79	annexin A13	Homo sapiens	93-96
2569497-6	1989	The antagonism by pindolol of 8-OH-DPAT-induced effects on male rat sexual behavior suggests an involvement of 5-HT1A receptors in the facilitation of this behavior produced by 8-OH-DPAT.	Pindolol	18-26	5-hydroxytryptamine receptor 1A	Rattus norvegicus	111-117
2907348-7	1988	Accordingly, pindolol can be subclassified as a partial beta 2-adrenoceptor agonist.	Pindolol	13-21	adrenoceptor beta 2	Homo sapiens	56-75
2901994-4	1988	In the current studies, we show that several beta AR antagonists with ISA (dichloroisoproterenol, pindolol, and celiprolol) stimulate cAMP accumulation five-, two-, and threefold, respectively, in S49 lymphoma cells, but only if cells are simultaneously incubated with the diterpene forskolin.	Pindolol	98-106	adrenergic receptor, beta 1	Mus musculus	45-52
2892553-2	1987	The effect of isoprenaline (10 microM at 37 degrees C for 30 min) pretreatment on [125I]-(-)-pindolol ([125I]-(-)-Pin) binding to beta 2-adrenoceptors on intact human platelets has been examined.	Pindolol	89-101	dynein light chain LC8-type 1	Homo sapiens	114-117
2971358-0	1988	Antagonism of 5-hydroxytryptamine1A (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers.	Pindolol	107-115	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-35
2971358-0	1988	Antagonism of 5-hydroxytryptamine1A (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers.	Pindolol	107-115	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
2971358-1	1988	The interactions of the stereoisomers of pindolol and propranolol with 5-hydroxytryptamine1A (5-HT1A) binding sites and adenylate cyclase activity were examined in rat hippocampus.	Pindolol	41-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-92
2971358-1	1988	The interactions of the stereoisomers of pindolol and propranolol with 5-hydroxytryptamine1A (5-HT1A) binding sites and adenylate cyclase activity were examined in rat hippocampus.	Pindolol	41-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	94-100
2971358-2	1988	(-)Pindolol and (-)propranolol displayed high affinity for 5-HT1A binding sites, and their affinities were not affected significantly by the addition of 10(-4) M GTP to the radioligand assay.	Pindolol	3-11	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-65
2971358-6	1988	These data suggest that (-)pindolol and (-)propranolol are potent antagonists at 5-HT1A receptors in rat hippocampus.	Pindolol	27-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
3376842-4	1988	The mean slope of the ESP/ESD relation was 36.3 +/- 20.4 mm Hg/cm at baseline and increased to 45.0 +/- 25.2 mm Hg/cm following five consecutive 10 mg oral doses of pindolol (p = ns).	Pindolol	165-173	protein tyrosine phosphatase receptor type V, pseudogene	Homo sapiens	22-25
2901112-6	1988	(-)-Pindolol, a potent 5-HT1A antagonist, prevented gepirone- and ipsapirone-induced hypothermia and corticosterone secretion.	Pindolol	0-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	23-29
3154682-7	1988	Serum insulin levels during oral glucose tolerance test at 120 min were decreased after pindolol therapy, but no significant changes were found in C-peptide levels during treatment periods.	Pindolol	88-96	insulin	Homo sapiens	6-13
2892553-2	1987	The effect of isoprenaline (10 microM at 37 degrees C for 30 min) pretreatment on [125I]-(-)-pindolol ([125I]-(-)-Pin) binding to beta 2-adrenoceptors on intact human platelets has been examined.	Pindolol	89-101	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	130-136
2893634-22	1987	While pindolol is a non-selective antagonist its agonist activity is mainly at the beta 2-adrenoceptor.	Pindolol	6-14	adrenoceptor beta 2	Homo sapiens	83-102
2888869-0	1987	Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.	Pindolol	121-129	adrenoceptor beta 1	Rattus norvegicus	24-43
2951504-6	1987	RU 24969 and (-)pindolol are approximately 2 orders of magnitude less potent at these sites than at 5-HT1B sites which have been identified in rat brain.	Pindolol	16-24	5-hydroxytryptamine receptor 1B	Rattus norvegicus	100-106
2893676-0	1987	(+/-)-Pindolol has beta 2-adrenoceptor antagonist but not agonist action on the costo-uterine muscle of the rat.	Pindolol	0-14	adrenoceptor beta 2	Rattus norvegicus	19-38
2888869-5	1987	Pindolol, xamoterol and cicloprolol behaved as competitive beta-1 adrenoceptor antagonists against isoproterenol-induced tachycardia in a pithed rat model.	Pindolol	0-8	adrenoceptor beta 1	Rattus norvegicus	59-78
2888869-7	1987	In this in vivo preparation, xamoterol and pindolol were more potent beta-1 adrenoceptor antagonists than cicloprolol; however, cicloprolol and xamoterol, in contrast to pindolol, were selective for beta-1 adrenoceptors.	Pindolol	43-51	adrenoceptor beta 1	Rattus norvegicus	69-88
2956114-3	1987	The corticosterone and beta-END responses to 8-OH-DPAT were antagonized by spiperone and (-)-pindolol, both of which have been shown to have high affinity for the 5-HT1A binding site.	Pindolol	89-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	163-169
2883987-8	1987	These results suggest that pindolol probably produces its partial agonist activity at both beta 1- and beta 2-adrenoceptors, while the partial agonist activity of epanolol is beta 1-selective.	Pindolol	27-35	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	91-109
2883987-8	1987	These results suggest that pindolol probably produces its partial agonist activity at both beta 1- and beta 2-adrenoceptors, while the partial agonist activity of epanolol is beta 1-selective.	Pindolol	27-35	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	91-97
3517076-4	1986	Mean basal plasma renin activity rose significantly from 0.45 +/- 0.44 to 1.42 +/- 1.31 ng/mL/hr and from 0.67 +/- 0.46 to 1.27 +/- 0.83 ng/mL/hr in patients receiving hydrochlorothiazide and combination therapy, respectively, but there was no change in those administered pindolol.	Pindolol	273-281	renin	Homo sapiens	18-23
2883645-0	1987	Beta 1- and beta 2-adrenoceptor affinity and stimulatory effects of (S)-pindolol and iodinated (S)-pindolol.	Pindolol	68-80	adrenoceptor beta 1	Rattus norvegicus	0-31
2883645-0	1987	Beta 1- and beta 2-adrenoceptor affinity and stimulatory effects of (S)-pindolol and iodinated (S)-pindolol.	Pindolol	95-107	adrenoceptor beta 1	Rattus norvegicus	0-31
2894222-0	1987	Is the ISA of pindolol beta 2-adrenoceptor selective?	Pindolol	14-22	adrenoceptor beta 2	Homo sapiens	23-42
2894222-5	1987	In vitro studies with pindolol show that its maximum stimulant action is similar to that of isoprenaline in tissues possessing mainly beta 2-adrenoceptors, but is negligible in tissues possessing mainly beta 1-adrenoceptors.	Pindolol	22-30	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	134-140
2894222-5	1987	In vitro studies with pindolol show that its maximum stimulant action is similar to that of isoprenaline in tissues possessing mainly beta 2-adrenoceptors, but is negligible in tissues possessing mainly beta 1-adrenoceptors.	Pindolol	22-30	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	203-209
2894222-8	1987	In man the arteriodilator effects observed after intra-arterially infused pindolol at concentrations within the same range as those producing an antihypertensive effect also suggest a stimulant action on vascular beta 2-adrenoceptors.	Pindolol	74-82	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	213-219
2894222-10	1987	The fact that pindolol prevents the reduction of resting heart rate and cardiac output observed after drugs lacking ISA at first sight suggests stimulation of cardiac beta 1-adrenoceptors.	Pindolol	14-22	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	167-173
2894222-16	1987	The evidence available therefore suggests that although pindolol blocks both beta 1- and beta 2-subtypes, it selectively stimulates beta 2-adrenoceptors.	Pindolol	56-64	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	77-95
2894222-16	1987	The evidence available therefore suggests that although pindolol blocks both beta 1- and beta 2-subtypes, it selectively stimulates beta 2-adrenoceptors.	Pindolol	56-64	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	89-95
2871880-0	1986	The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat.	Pindolol	86-94	adrenoceptor beta 1	Rattus norvegicus	4-35
2871880-14	1986	6 It is concluded that weak partial agonists such as alprenolol, oxprenolol and pindolol possess complex beta 1- and beta 2-adrenoceptor stimulatory properties in relation to beta-adrenoceptor occupancy and tissue sensitivity to beta-adrenoceptor stimulation.	Pindolol	80-88	adrenoceptor beta 1	Rattus norvegicus	105-136
3326631-13	1987	It is as yet unclear whether the ISA or beta 2-mediated vasodilation associated with pindolol was responsible for the improved foetal growth.	Pindolol	85-93	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	40-46
3588365-0	1986	[Effect of treatment with pindolol on the renin-angiotensin-aldosterone system, kidney function and electrolyte balance in patients with primary arterial hypertension].	Pindolol	26-34	renin	Homo sapiens	42-47
2877087-3	1986	Several noncardioselective, beta-2 adrenoceptor antagonists with intrinsic sympathomimetic activity (ISA) also inhibited the activity of the ligament: pindolol greater than alprenolol = bucindolol = oxprenolol greater than labetalol.	Pindolol	151-159	adrenoceptor beta 2	Rattus norvegicus	28-47
2881017-5	1986	Pindolol (beta 1 + beta 2-blocker but is devoid of membrane stabilizing activity) suppressed the development of tolerance to morphine analgesia; however, d-propranolol, which possesses membrane stabilizing activity but lacks beta-blocking activity, could not prevent the development of tolerance.	Pindolol	0-8	hemoglobin, beta adult major chain	Mus musculus	10-16
2881017-5	1986	Pindolol (beta 1 + beta 2-blocker but is devoid of membrane stabilizing activity) suppressed the development of tolerance to morphine analgesia; however, d-propranolol, which possesses membrane stabilizing activity but lacks beta-blocking activity, could not prevent the development of tolerance.	Pindolol	0-8	hemoglobin, beta adult minor chain	Mus musculus	19-25
2878948-3	1986	A significant decrease in serum Tg was also found in the oxprenolol-treated group [before start: 45 (24-423) micrograms/l and after 4h: 43 (18-363) micrograms/l (p less than 0.01)] and in the pindolol-treated group [before start: 154 (33-210) micrograms/l and after 4 h: 63 (19-157) micrograms/l (p less than 0.05) treated groups.	Pindolol	192-200	thyroglobulin	Homo sapiens	32-34
2878948-4	1986	After 7 days treatment the decrease in serum Tg was significant [to 85 (34-182) micrograms/l (p less than 0.02)] only in the Pindolol-treated group.	Pindolol	125-133	thyroglobulin	Homo sapiens	45-47
2879589-5	1986	The results are consistent with a moderate selectivity of (-)-pindolol for beta 2-compared to beta 1-adrenoceptors in human atrium.	Pindolol	58-70	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	75-81
2879589-8	1986	The affinity of (-)-pindolol estimated for human myocardial beta-adrenoceptors, its moderate beta 2-selectivity and its lack of intrinsic activity for contractile force agreed with similar characteristics in other species.	Pindolol	16-28	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	93-99
2875397-2	1986	In the present study the effects of pindolol [non-selective beta-adrenoceptor antagonist with strong partial agonistic activity (PAA)] on beta 2-adrenoceptor density in lymphocytes (assessed by (-)-[125I]iodocyanopindolol (ICYP) binding) were compared with those of the beta 1-selective antagonists celiprolol (with PAA) and bisoprolol (no PAA) in normotensive young volunteers to get further insights into the nature of PAA.	Pindolol	36-44	adrenoceptor beta 2	Homo sapiens	138-157
2875397-3	1986	Administration of pindolol (2 X 5 mg/day) caused an about 25% decrease in lymphocyte beta 2-adrenoceptor density after 2 days; during treatment beta 2-adrenoceptor density declined further (maximum decrease after 7 days: 50%).	Pindolol	18-26	adrenoceptor beta 2	Homo sapiens	85-104
2875397-4	1986	After withdrawal of pindolol lymphocyte beta 2-adrenoceptor density recovered very slowly being still after 4 days significantly reduced, although no pindolol was detectable in plasma after 36 h. The KD-values for ICYP, however, did not change during or after pindolol treatment.	Pindolol	20-28	adrenoceptor beta 2	Homo sapiens	40-59
2875397-5	1986	The decrease in lymphocyte beta 2-adrenoceptor density induced by pindolol could be completely prevented by simultaneous administration of propranolol (3 X 40 mg/day) indicating that the PAA of pindolol is the cause of its beta-adrenoceptor decreasing effect.	Pindolol	66-74	adrenoceptor beta 2	Homo sapiens	27-46
2875397-5	1986	The decrease in lymphocyte beta 2-adrenoceptor density induced by pindolol could be completely prevented by simultaneous administration of propranolol (3 X 40 mg/day) indicating that the PAA of pindolol is the cause of its beta-adrenoceptor decreasing effect.	Pindolol	194-202	adrenoceptor beta 2	Homo sapiens	27-46
3946248-9	1986	The hemodynamic differences between the 2 agents can probably be explained by the fact that pindolol with its intrinsic sympathomimetic activity acts as a partial agonist causing active stimulation of vascular beta 2 adrenoceptors and relaxation of resistance vessels.	Pindolol	92-100	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	210-216
2867205-9	1985	Growing cells in the presence of pindolol or celiprolol induced a 50% decrease in the density of beta-2 receptors, which was inhibited by beta adrenergic antagonists.	Pindolol	33-41	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	97-103
2874067-4	1986	In the pindolol group an improvement in renal function was observed as determined by CCT and serum creatinine.	Pindolol	7-15	CCT	Homo sapiens	85-88
2439825-8	1986	Pindolol treatment (2 X 5 mg/day) caused a 50% decrease of beta 2-adrenoceptor density after 2 days, which remained reduced during treatment.	Pindolol	0-8	adrenoceptor beta 2	Homo sapiens	59-78
6430812-0	1984	Long-term effect of pindolol on plasma lipids, apoproteins A, blood glucose, and serum insulin levels.	Pindolol	20-28	insulin	Homo sapiens	87-94
2409357-8	1985	The concentration of apolipoprotein A-I increased slightly during pindolol therapy.	Pindolol	66-74	apolipoprotein A1	Homo sapiens	21-39
6100755-5	1984	The vasodilator effect of pindolol cannot easily be explained by suppression of plasma renin activity since changes in arterial pressure and plasma renin were inversely correlated (r = -0.58, P less than 0.001).	Pindolol	26-34	renin	Homo sapiens	148-153
6241568-6	1984	In contrast, both behaviours in the reserpinised rat were inhibited stereospecifically by pindolol and by spiperone, which interact with 5-HT1 and 5-HT1A recognition sites.	Pindolol	90-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	147-153
2859784-8	1985	The concentration of apolipoprotein A-I increased slightly during pindolol therapy.	Pindolol	66-74	apolipoprotein A1	Homo sapiens	21-39
2988977-0	1985	Pindolol decreases plasma angiotensin-converting enzyme activity in young spontaneously hypertensive rats.	Pindolol	0-8	angiotensin I converting enzyme	Rattus norvegicus	26-55
2988977-5	1985	A decrease in soluble (loosely bound) ACE activity was observed in the lung of young SHR treated with pindolol.	Pindolol	102-110	angiotensin I converting enzyme	Rattus norvegicus	38-41
2988977-6	1985	The results suggest that pindolol affects the site of origin of plasma ACE.	Pindolol	25-33	angiotensin I converting enzyme	Rattus norvegicus	71-74
2988977-7	1985	The susceptibility of young SHR to pindolol may indicate a probable role of beta-adrenoceptors in the regulation of ACE activity in spontaneous (genetic) hypertension.	Pindolol	35-43	angiotensin I converting enzyme	Rattus norvegicus	116-119
2986991-0	1985	The sympathomimetic activity of (+/-)-pindolol at beta 1- and beta 2-adrenoceptor sites.	Pindolol	32-46	adrenoceptor beta 1	Rattus norvegicus	50-81
3904336-1	1985	The effects on plasma lipids, blood glucose and serum insulin levels of oral administration of trimazosin and pindolol over a 6-month period were studied in 11 patients with essential hypertension.	Pindolol	110-118	insulin	Homo sapiens	54-61
6360452-3	1983	Both pindolol and propranolol suppressed the significant orthostatic rise of plasma renin activity (PRA) seen without medication.	Pindolol	5-13	renin	Homo sapiens	84-89
6826021-4	1983	It is concluded that the intrinsic sympathomimetic activity of pindolol is exerted principally on the beta 2-adrenoceptor.	Pindolol	63-71	beta-2 adrenergic receptor	Cavia porcellus	102-121
6360452-0	1983	Effect of pindolol and propranolol on plasma renin and aldosterone in patients with renal allograft.	Pindolol	10-18	renin	Homo sapiens	45-50
6137325-6	1983	Increases in LDL-C caused by chlorthalidone monotherapy were prevented or reversed by the addition of a beta-blocker, usually propranolol or atenolol (n = 18); increases in LDL-C during clopamide monotherapy were reversed after the addition of the beta-blocker pindolol (10 mg/day, n = 17).	Pindolol	261-269	component of oligomeric golgi complex 2	Homo sapiens	13-18
6342904-7	1983	Basal plasma renin activity was reduced slightly and the increase of stimulated plasma renin was blunted by pindolol even after 4 wk.	Pindolol	108-116	renin	Homo sapiens	87-92
6342904-8	1983	The initial lowering of unstimulated renin by pindolol in the first 2 hr after dosing was not detectable after 4 wk.	Pindolol	46-54	renin	Homo sapiens	37-42
6139318-1	1983	Administration of a beta-blocker, pindolol, was utilized in the premedication of patients selected for tonsillectomies (dissection), to study anxiolytic effects.	Pindolol	34-42	amyloid beta precursor protein	Homo sapiens	18-24
6760678-11	1982	This was probably an effect of beta 2-adrenoceptor stimulation linked to the pronounced intrinsic sympathomimetic activity (ISA) of pindolol.	Pindolol	132-140	adrenoceptor beta 2	Bos taurus	31-50
7048878-0	1982	Pindolol: effects on blood pressure and plasma renin activity.	Pindolol	0-8	renin	Homo sapiens	47-52
7043175-3	1982	Following addition of pindolol, serum LDL-C was restored to control values.	Pindolol	22-30	component of oligomeric golgi complex 2	Homo sapiens	38-43
7043175-6	1982	These findings suggest that antihypertensive combination treatment with low doses of clopamide and pindolol is not only effective and well tolerated, but may also avoid the increase in serum LDL-C levels occurring when the thiazide-like diuretic is given alone.	Pindolol	99-107	component of oligomeric golgi complex 2	Homo sapiens	191-196
6138468-5	1983	The concentration of apolipoprotein A-I and the ratio of A-I to apoprotein A-II increased slightly but not significantly during pindolol treatment.	Pindolol	128-136	apolipoprotein A1	Homo sapiens	21-39
6138471-2	1983	The effects of oral doses of pindolol, metoprolol, and propranolol on the response to insulin-induced hypoglycemia and an oral glucose load were investigated.	Pindolol	29-37	insulin	Homo sapiens	86-93
7116756-4	1982	Intravenous pindolol resulted in decreased mean heart rate (74.3 to 67 bpm) and decreased mean inulin clearance (66 to 60.5 ml/min/1.73 m2.)	Pindolol	12-20	CD59 molecule (CD59 blood group)	Homo sapiens	127-132
7102532-2	1982	Pindolol responders with normal pretreatment preejection period to left ventricular ejection time (PEP/LVET) ratios had a significant increase in this ratio following pindolol therapy, whereas those with abnormal pretreatment PEP/LVET ratios had improvement in this ratio on administration of the drug.	Pindolol	0-8	progestagen associated endometrial protein	Homo sapiens	99-102
7102532-2	1982	Pindolol responders with normal pretreatment preejection period to left ventricular ejection time (PEP/LVET) ratios had a significant increase in this ratio following pindolol therapy, whereas those with abnormal pretreatment PEP/LVET ratios had improvement in this ratio on administration of the drug.	Pindolol	0-8	progestagen associated endometrial protein	Homo sapiens	226-229
7102532-2	1982	Pindolol responders with normal pretreatment preejection period to left ventricular ejection time (PEP/LVET) ratios had a significant increase in this ratio following pindolol therapy, whereas those with abnormal pretreatment PEP/LVET ratios had improvement in this ratio on administration of the drug.	Pindolol	167-175	progestagen associated endometrial protein	Homo sapiens	99-102
7102534-4	1982	On day 0, beta blockade was evident by increased CD25 values of 618 micrograms for pindolol, 57 micrograms for propranolol, and 10 micrograms for metoprolol as compared to 2.8, 2.4, and 3.0 microgram, respectively, at days 14 to 21, which were considered the ultimate baseline.	Pindolol	83-91	interleukin 2 receptor subunit alpha	Homo sapiens	49-53
7102534-5	1982	After pindolol on day 0, the CD25 slowly decreased to, but never below, baseline by days 8 to 21.	Pindolol	6-14	interleukin 2 receptor subunit alpha	Homo sapiens	29-33
6126816-10	1982	dl-Celiprolol or dl-pindolol, beta-adrenoceptor antagonists with ISA, but cardioselective or non-selective enhance both, basal insulin level and insulin level after glucose stimulation but must be assumed to decrease peripheral glucose uptake since here too glucose tolerance was unchanged.	Pindolol	17-28	insulin	Canis lupus familiaris	127-134
6291825-17	1982	Comparison between the cardiovascular responses to the non-selective beta-adrenoceptor agonist isoprenaline and the beta 2-selective agonist salbutamol suggest preferential beta 2-adrenoceptor sensitization in chronic autonomic failure, which can be reversed by treatment with the non-selective partial beta-adrenoceptor agonist pindolol.	Pindolol	329-337	adrenoceptor beta 2	Homo sapiens	173-192
7117354-9	1982	Therefore, the dose of pindolol could have been reduced by a factor 2, but the reduction was not essential.	Pindolol	23-31	transcription termination factor 2	Homo sapiens	61-69
7104147-3	1982	2 The long-term administration of pindolol (5--20 mg/day) to hypertensive patients with normal renal function was not associated with changes in renal function but in patients with a decreased renal function, pindolol caused an increase in PAH clearance but no change in inulin clearance.	Pindolol	34-42	phenylalanine hydroxylase	Homo sapiens	240-243
7104147-3	1982	2 The long-term administration of pindolol (5--20 mg/day) to hypertensive patients with normal renal function was not associated with changes in renal function but in patients with a decreased renal function, pindolol caused an increase in PAH clearance but no change in inulin clearance.	Pindolol	209-217	phenylalanine hydroxylase	Homo sapiens	240-243
7104148-2	1982	2 Pindolol caused a smaller decrease in plasma renin activity and heart rate than propranolol.	Pindolol	2-10	renin	Homo sapiens	47-52
7104154-6	1982	After pindolol we observed a CD25 below baseline only in one case with no corresponding reaction in the exercise test.	Pindolol	6-14	interleukin 2 receptor subunit alpha	Homo sapiens	29-33
7104157-6	1982	5 Compared with the placebo period, both pindolol and metoprolol significantly reduced heart rate (HR) and systolic (SBP) and diastolic (DBP) blood pressure.	Pindolol	41-49	selenium binding protein 1	Homo sapiens	117-120
7104157-6	1982	5 Compared with the placebo period, both pindolol and metoprolol significantly reduced heart rate (HR) and systolic (SBP) and diastolic (DBP) blood pressure.	Pindolol	41-49	D-box binding PAR bZIP transcription factor	Homo sapiens	137-140
7104159-7	1982	6 LCAT activity was significantly higher (P less than 0.01) during pindolol treatment than after the break in it.	Pindolol	67-75	lecithin-cholesterol acyltransferase	Homo sapiens	2-6
6119937-2	1981	Agents with ISA such as pindolol produce effective beta-blockade during effort or emotional stress while conferring significant protection from myocardial depression and bradycardia at rest.	Pindolol	24-32	annexin A13	Homo sapiens	12-15
7314090-1	1981	We observed elevation of serum CPK in hypertensive patients under pindolol treatment.	Pindolol	66-74	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	31-34
7027387-0	1981	[Effects of propranolol and pindolol on cardiovascular and plasma catecholamine and renin responses to exercise (author"s transl)].	Pindolol	28-36	renin	Homo sapiens	84-89
6117308-3	1981	2 The CSF concentration of propranolol (lipid-soluble) and pindolol (moderately lipid-soluble) was proportional to the free plasma concentration and was similar to, although generally lower than, that theoretically predicted.	Pindolol	59-67	colony stimulating factor 2	Homo sapiens	6-9
7314090-3	1981	Mean serum CPK values in the patients under pindolol treatment and propranolol treatment were 117.0 +/- 12.6 (S.E.)	Pindolol	44-52	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	11-14
7314090-5	1981	Although the mechanism of elevation of serum CPK cannot be well understood, we should be careful in clinical evaluation of serum CPK during pindolol treatment.	Pindolol	140-148	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	129-132
6117193-4	1981	After changing to a beta-blocker with a high degree of intrinsic sympathomimetic activity (pindolol), hand blood flow increased and sensitivity to cold decreased in all patients, except one.	Pindolol	91-99	amyloid beta precursor protein	Homo sapiens	18-24
7002425-4	1980	Oral pindolol (10 to 20 mg/day) for a mean of 6 mo resulted in a decrease in mean blood pressure from 124 to 111 mm Hg (p < 0.001), in mean pulse rate from 76 to 69/min (p < 0.005), and in mean plasma renin activity (PRA) from 0.9 to 0.29 ng/ml/hr (p < 0.05).	Pindolol	5-13	renin	Homo sapiens	207-212
7314090-2	1981	In this report, we showed a representative patient and compared serum CPK values in 56 patients under pindolol treatment to those in 64 patients under propranolol treatment.	Pindolol	102-110	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	70-73
6102616-1	1980	Effects of dl-, d-, l-propranolol and pindolol on renin release.	Pindolol	38-46	renin	Rattus norvegicus	50-55
6103674-2	1980	The nonselective beta-adrenoceptor blocking drugs propranolol, D-32, and pindolol significantly inhibited increases in heart rate and plasma renin activity and a fall of blood pressure produced by intravenous infusion of isoproterenol (10 microgram .	Pindolol	73-81	renin	Canis lupus familiaris	141-146
6102616-2	1980	In order to reveal the mechanism of renin inhibition by beta adrenergic blocking agents, the effects of dl-, d-, l-propranolol and pindolol on renin release were studied.	Pindolol	131-139	renin	Rattus norvegicus	143-148
6102616-6	1980	Pindolol also inhibited renin release, but its effects were significantly less than those of other agents.	Pindolol	0-8	renin	Rattus norvegicus	24-29
399210-0	1979	[Effects of pindolol on arterial pressure and plasma renin activity in essential hypertension and in hypertension during chronic renal insufficiency].	Pindolol	12-20	renin	Homo sapiens	53-58
41815-7	1979	After beta-receptor blockade with either Bufuralol-hydrochloride or with Pindolol a shift to the right of the dose effect relationship concerning heart rate and cardiac output under Isoproterenol infusion was observed, indicating beta 1-blockade.	Pindolol	73-81	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	230-236
400001-0	1979	[Effects of pindolol on insulin secretion.	Pindolol	12-20	insulin	Homo sapiens	24-31
400001-2	1979	Insulin response to small intravenous loads of glucose and to pindolol infusion].	Pindolol	62-70	insulin	Homo sapiens	0-7
396760-0	1979	Species differences in the effect of isoproterenol and pindolol on renin release in vitro.	Pindolol	55-63	renin	Canis lupus familiaris	67-72
396760-1	1979	The effects of selective beta adrenergic receptor stimulation with isoproterenol (3 X 10(-8) M) and of beta adrenergic blockade with pindolol (3 X 10(-5) M) on the renin release in vitro were investigated in incubated canine and rat kidney slices.	Pindolol	133-141	renin	Canis lupus familiaris	164-169
396760-4	1979	Pindolol, on the other hand, in a concentration of 3 X 10(-5) M caused a significant decrease in the renin release from as well as in the renin content of the rat kidney slices, while canine kidney slices failed to respond to the same dose of the drug.	Pindolol	0-8	renin	Rattus norvegicus	101-106
396760-4	1979	Pindolol, on the other hand, in a concentration of 3 X 10(-5) M caused a significant decrease in the renin release from as well as in the renin content of the rat kidney slices, while canine kidney slices failed to respond to the same dose of the drug.	Pindolol	0-8	renin	Rattus norvegicus	138-143
363480-1	1978	Two groups of twenty-five hypertensive patients each were treated with a beta-adrenergic blocking agent (pindolol), either alone or in combination with classical anthihypertensives.	Pindolol	105-113	amyloid beta precursor protein	Homo sapiens	71-77
495127-0	1979	Alleviating effect of pindolol in HgCL2-induced acute renal failure in rats: effect of HgCl2 and pindolol on renin release in vitro.	Pindolol	97-105	renin	Rattus norvegicus	109-114
411662-0	1977	The effect of pindolol on plasma renin activity in patients with essential hypertension.	Pindolol	14-22	renin	Homo sapiens	33-38
411662-3	1977	After treatment with pindolol the plasma renin activity was significantly lower.	Pindolol	21-29	renin	Homo sapiens	41-46
322092-4	1977	The highly significant fall in blood pressure (delta SBP and delta DBP) is directly correlated negatively correlated, to the pretreatment pressure (p less than 0.02 for deltaSBP and p less than 0.05 deltaDBP) and negatively correlated to the pindolol plasma level (P less than 0.001 for delta SBP and p less than 0.05 for delta DBP).	Pindolol	242-250	selenium binding protein 1	Homo sapiens	53-56
322092-4	1977	The highly significant fall in blood pressure (delta SBP and delta DBP) is directly correlated negatively correlated, to the pretreatment pressure (p less than 0.02 for deltaSBP and p less than 0.05 deltaDBP) and negatively correlated to the pindolol plasma level (P less than 0.001 for delta SBP and p less than 0.05 for delta DBP).	Pindolol	242-250	D-box binding PAR bZIP transcription factor	Homo sapiens	67-70
899884-0	1977	Blood pressure and renin during treatment with pindolol.	Pindolol	47-55	renin	Homo sapiens	19-24
973972-0	1976	The effect of pindolol on plasma renin activity and blood pressure in hypertensive patients.	Pindolol	14-22	renin	Homo sapiens	33-38
864907-0	1977	[Aldosteronemia and plasma renin activity in patients with hypertension treated with visken (prindolol)].	Pindolol	85-91	renin	Homo sapiens	27-32
864907-0	1977	[Aldosteronemia and plasma renin activity in patients with hypertension treated with visken (prindolol)].	Pindolol	93-102	renin	Homo sapiens	27-32
1011973-0	1976	[Effect of Prindolol on intra-arterial pressure and plasma renin activity in essential hypertension].	Pindolol	11-20	renin	Homo sapiens	59-64
996500-0	1976	[Blood pressure and renin activity in essential hypertension under pindolol].	Pindolol	67-75	renin	Homo sapiens	20-25
1266560-2	1976	The beneficial effect of a beta-blocking agent (pindolol), given as an adjuvant to DC-shock and lidocaine therapy in a case of heart resuscitation is reported.	Pindolol	48-56	amyloid beta precursor protein	Homo sapiens	25-31
1215927-0	1975	[Proceedings: The effect of beta receptor treatment with pindolol on the plasma renin activity and the left-ventricular dynamics in essential hypertension].	Pindolol	57-65	renin	Homo sapiens	80-85
1032571-0	1976	[Effect of pindolol (Visken) on blood pressure and plasma renin activity in various forms of hypertension].	Pindolol	11-19	renin	Homo sapiens	58-63
802647-2	1975	Prindolol and propranolol chronically cause a fall in mean blood pressure and mean plasma renin activity, but no correlation was observed between the two variables.	Pindolol	0-9	renin	Homo sapiens	90-95
1241067-0	1975	Effect of propranolol and prindolol on renin secretion in normal supine man.	Pindolol	26-35	renin	Homo sapiens	39-44
1241067-4	1975	Both in propranolol and in prindolol-treated subjects secretory episodes in renin secretion either did not occur or were less frequent than in normal controls.	Pindolol	27-36	renin	Homo sapiens	76-81
791319-1	1975	1 Propranolol and pindolol reduced both the blood pressure and plasma renin activity when given chronically to hypertensive patients.	Pindolol	18-26	renin	Homo sapiens	70-75
1149326-0	1975	The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels.	Pindolol	37-45	renin	Homo sapiens	108-113
1227043-0	1975	[Episodical renin secretion during propranolol and pindolol administration in normal subjects].	Pindolol	51-59	renin	Homo sapiens	12-17
4824603-0	1974	Inhibition of vasopressin-induced morbid effects on the rat kidney by pindolol and propranolol.	Pindolol	70-78	arginine vasopressin	Rattus norvegicus	14-25
4374990-0	1973	[Kinetic study on the renin-angiotensin system in the presence of a beta-blockader: pindolol].	Pindolol	84-92	renin	Homo sapiens	22-27
4398483-0	1971	[Effect of LB46 (a beta-adrenergic blockader) on chronic atrial fibrillation].	Pindolol	11-15	amyloid beta precursor protein	Homo sapiens	17-23
32677492-0	2022	Pindolol potentiate the antidepressant effect of venlafaxine by inhibiting 5-HT1A receptor in DRN neurons of mice.	Pindolol	0-8	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	75-90
4149613-3	1974	When prindolol, another beta-adrenergic blocking drug, was substituted for propranolol, blood pressure control was retained, but there was a prompt rise in plasma renin activity, which was not attributable to changes in electrolyte balance.	Pindolol	5-14	renin	Homo sapiens	163-168
32677492-2	2022	Pindolol may eliminate this inhibition when used in combination with antidepressants.Material and methods: We aimed to determine the effect of pindolol on 5-HT1A receptor response in the DRN neurons, using voltage clamp recordings and prove the potentiation of antidepressant effect of venlafaxine by pindolol through behavior experiments.	Pindolol	0-8	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	155-170
32534819-9	2020	Pretreatment of mice with 5HT1A antagonist pindolol (10 mg/kg, i.p) or GABAA antagonist bicuculline (2 mg/kg, i.p) significantly attenuated the effect of 5-methoxyflavone in the elevated plus maze test.	Pindolol	43-51	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	26-31
32677492-2	2022	Pindolol may eliminate this inhibition when used in combination with antidepressants.Material and methods: We aimed to determine the effect of pindolol on 5-HT1A receptor response in the DRN neurons, using voltage clamp recordings and prove the potentiation of antidepressant effect of venlafaxine by pindolol through behavior experiments.	Pindolol	143-151	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	155-170
32677492-2	2022	Pindolol may eliminate this inhibition when used in combination with antidepressants.Material and methods: We aimed to determine the effect of pindolol on 5-HT1A receptor response in the DRN neurons, using voltage clamp recordings and prove the potentiation of antidepressant effect of venlafaxine by pindolol through behavior experiments.	Pindolol	301-309	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	155-170
31971372-5	2020	The cationic beta-blocker pindolol was injected electrokinetically, and detected at concentrations ranging from 10 nM to 5 muM, with an estimated detection limit of 2 nM.	Pindolol	26-34	latexin	Homo sapiens	123-126
28369986-4	2017	Mesoporous silica functionalized with octadecyl groups (denoted SBA15-C18) was prepared by a postsynthesis method and applied for the preconcentration of atenolol, propranolol, metoprolol, and pindolol enantiomers in waters by off-line SPE.	Pindolol	193-201	Bardet-Biedl syndrome 9	Homo sapiens	70-73
31849624-7	2019	We also show that chronic (2 weeks) pindolol treatment (32 mg/kg/day) attenuates alcohol-induced impairments in the density of immature neurons (DCX+) but not newborn cells (BrdU+) in the hippocampal DG.	Pindolol	36-44	doublecortin	Mus musculus	145-148
31849624-8	2019	Pindolol treatment also restores the normal proportion of newborn proliferating cells (BrdU+/Ki67+/DCX-), newborn proliferating immature neurons (BrdU+/Ki67+/DCX+) and newborn non-proliferating immature neurons (BrdU+/Ki67-/DCX+) following long-term alcohol intake.	Pindolol	0-8	doublecortin	Mus musculus	99-102
31849624-8	2019	Pindolol treatment also restores the normal proportion of newborn proliferating cells (BrdU+/Ki67+/DCX-), newborn proliferating immature neurons (BrdU+/Ki67+/DCX+) and newborn non-proliferating immature neurons (BrdU+/Ki67-/DCX+) following long-term alcohol intake.	Pindolol	0-8	doublecortin	Mus musculus	158-161
31849624-8	2019	Pindolol treatment also restores the normal proportion of newborn proliferating cells (BrdU+/Ki67+/DCX-), newborn proliferating immature neurons (BrdU+/Ki67+/DCX+) and newborn non-proliferating immature neurons (BrdU+/Ki67-/DCX+) following long-term alcohol intake.	Pindolol	0-8	doublecortin	Mus musculus	158-161
30783717-8	2019	The antidepressant-like effects of the new compounds in the FST were prevented by pretreatment of mice with pCPA (serotonin depletor), (-)pindolol (mixed 5-HT1A/1B and beta-adrenergic antagonist), and WAY 100635 (selective 5-HT1A antagonist).	Pindolol	135-146	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	154-160
30783717-8	2019	The antidepressant-like effects of the new compounds in the FST were prevented by pretreatment of mice with pCPA (serotonin depletor), (-)pindolol (mixed 5-HT1A/1B and beta-adrenergic antagonist), and WAY 100635 (selective 5-HT1A antagonist).	Pindolol	135-146	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	223-229
29174531-7	2018	Hence, the mixed ss-adrenoceptor/5-HT1A antagonist pindolol accelerated, and in some cases enhanced, the clinical action of selective serotonin reuptake inhibitors (SSRI).	Pindolol	51-59	5-hydroxytryptamine receptor 1A	Homo sapiens	33-39
28063918-11	2017	Pindolol, olanzapine, and ziprasidone were used as tool compounds for demonstrating receptor occupancy at 5-HT1A, 5-HT2A, and D2 receptors.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-112
25610919-6	2015	Consequently the electroanalytical sensing of pindolol is explored at bare unmodified SPEs where a linear range between 0.1 muM-10.0 muM is found to be possible whilst offering a limit of detection (3sigma) corresponding to 0.097 muM.	Pindolol	46-54	latexin	Homo sapiens	124-127
26399643-5	2016	Unlike beta1-AR, binding of (125)I-pindolol to beta2-AR in cell membranes was significantly decreased at 2 h of exposure to TH which came back to control values after 24 h. The initial decrease in beta2-AR in membranes resulted in a concomitant increase in beta2-AR levels in the cytosol, suggesting that TH may induce endocytosis of the receptor.	Pindolol	35-43	adrenoceptor beta 2	Homo sapiens	47-55
26399643-5	2016	Unlike beta1-AR, binding of (125)I-pindolol to beta2-AR in cell membranes was significantly decreased at 2 h of exposure to TH which came back to control values after 24 h. The initial decrease in beta2-AR in membranes resulted in a concomitant increase in beta2-AR levels in the cytosol, suggesting that TH may induce endocytosis of the receptor.	Pindolol	35-43	adrenoceptor beta 2	Homo sapiens	197-205
26399643-5	2016	Unlike beta1-AR, binding of (125)I-pindolol to beta2-AR in cell membranes was significantly decreased at 2 h of exposure to TH which came back to control values after 24 h. The initial decrease in beta2-AR in membranes resulted in a concomitant increase in beta2-AR levels in the cytosol, suggesting that TH may induce endocytosis of the receptor.	Pindolol	35-43	adrenoceptor beta 2	Homo sapiens	197-205
25610919-6	2015	Consequently the electroanalytical sensing of pindolol is explored at bare unmodified SPEs where a linear range between 0.1 muM-10.0 muM is found to be possible whilst offering a limit of detection (3sigma) corresponding to 0.097 muM.	Pindolol	46-54	latexin	Homo sapiens	133-136
25610919-6	2015	Consequently the electroanalytical sensing of pindolol is explored at bare unmodified SPEs where a linear range between 0.1 muM-10.0 muM is found to be possible whilst offering a limit of detection (3sigma) corresponding to 0.097 muM.	Pindolol	46-54	latexin	Homo sapiens	133-136
25220702-8	2014	In contrast, prolactin levels remained similar to those of controls both in hyperestrogenic animals treated with 8-OH-DPAT and pindolol and in hypoestrogenic rats administered the same treatments.	Pindolol	127-135	prolactin	Rattus norvegicus	13-22
23291880-5	2013	Moreover, the antinociceptive activity of laser irradiation in the acetic acid test was significantly reversed by preadministration of naloxone (1 mg/kg, nonselective opioid receptor antagonist), pindolol (1 mg/kg, subcutaneous; nonselective 5-HT 1A/B receptor antagonist), and ketanserin (1 mg/kg; selective 5-HT2A receptor antagonist) but not by ondansetron (1 mg/kg, selective 5-HT3 receptor antagonist).	Pindolol	196-204	5-hydroxytryptamine receptor 3A	Rattus norvegicus	380-394
24272787-7	2014	Espindolol decreased proteasome and caspase-3 proteolytic activities by approximately 50 % (all p < 0.05).	Pindolol	0-10	caspase 3	Rattus norvegicus	36-45
23084984-0	2012	Both acute and subchronic treatments with pindolol, a 5-HT(1A) and beta1 and beta2 adrenoceptor antagonist, elevate regional serotonin synthesis in the rat brain: an autoradiographic study.	Pindolol	42-50	5-hydroxytryptamine receptor 1A	Rattus norvegicus	54-61
23607617-7	2013	However, only atenolol, pindolol, and ofloxacin were transported by hOCT2, the main OCT in human kidneys.	Pindolol	24-32	POU class 2 homeobox 2	Homo sapiens	68-73
23084984-0	2012	Both acute and subchronic treatments with pindolol, a 5-HT(1A) and beta1 and beta2 adrenoceptor antagonist, elevate regional serotonin synthesis in the rat brain: an autoradiographic study.	Pindolol	42-50	adrenoceptor beta 2	Rattus norvegicus	77-95
23084984-3	2012	The aim of the present study was to assess the effect of the acute and subchronic treatment with pindolol, a 5-HT(1A/1B,) beta1 and beta2 adrenoceptor antagonist, on 5-HT synthesis, one of the key parameters of 5-HT neurotransmission.	Pindolol	97-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	109-127
23084984-3	2012	The aim of the present study was to assess the effect of the acute and subchronic treatment with pindolol, a 5-HT(1A/1B,) beta1 and beta2 adrenoceptor antagonist, on 5-HT synthesis, one of the key parameters of 5-HT neurotransmission.	Pindolol	97-105	adrenoceptor beta 2	Rattus norvegicus	132-150
21421022-1	2011	The beta-adrenergic blocker and 5-HT(1A) receptor antagonist pindolol has been combined with selective serotonin reuptake inhibitors (SSRIs) in patients with depressive and anxiety disorders to shorten the onset of the clinical action and/or increase the proportion of responders.	Pindolol	61-69	5-hydroxytryptamine receptor 1A	Homo sapiens	32-39
22207908-5	2011	MT-102, a novel anabolic/catabolic transforming agent, has a multi-functional effect upon three potential pharmacological targets in cancer cachexia, namely reduced catabolism through non-selective beta-blockade, reduced fatigue, and thermogenesis through central 5-HT1a antagonism and increased anabolism through partial beta-2 receptor agonism.	Pindolol	0-6	5-hydroxytryptamine receptor 1A	Homo sapiens	264-270
22050051-2	2012	5-HT(1A) receptor antagonists augment antidepressant-like effects in rodents by preventing this negative feedback, and the mixed beta-adrenoceptor/5-HT(1A) receptor antagonist pindolol improves clinical antidepressant effects by preferentially interacting with 5-HT(1A) autoreceptors.	Pindolol	176-184	5-hydroxytryptamine receptor 1A	Homo sapiens	147-164
21562484-4	2011	Ketanserin is a 5-HT(2A) receptor blocker and pindolol a 5-HT(1A) receptor blocker.	Pindolol	46-54	5-hydroxytryptamine receptor 1A	Homo sapiens	57-64
21421022-3	2011	Since reported evidence has implicated the 5-HT(1A) receptors of the dorsal periaqueductal gray matter (DPAG) in the panicolytic effect of antidepressants, rats treated with pindolol (5.0mg/kg, i.p.)	Pindolol	174-182	5-hydroxytryptamine receptor 1A	Homo sapiens	43-50
21421022-7	2011	These results implicate the 5-HT(1A) receptors of the DPAG in the panicolytic effect of the pindolol-paroxetine combination administered systemically.	Pindolol	92-100	5-hydroxytryptamine receptor 1A	Homo sapiens	28-35
18194152-4	2008	In study 1, 10 IBS patients and 10 controls underwent pretreatment with pindolol (5HT1a antagonist) or placebo followed by buspirone.	Pindolol	72-80	5-hydroxytryptamine receptor 1A	Homo sapiens	82-87
19464246-4	2009	The europium-labeled pindolol ligands having no spacer (C0) or a 12-carbon spacer (C12) arm bound to the human beta(2)-adrenergic receptors overexpressed in human embryonic kidney HEK293(i) cells.	Pindolol	21-29	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	111-117
19429833-8	2009	Likewise, 10 nM SR 59230A reduced the effects of the beta(3)-adrenoceptor agonists BRL 37344, CGP 12177, SR 595611A, or pindolol.	Pindolol	120-128	adrenoceptor beta 3	Rattus norvegicus	53-73
18462818-10	2008	Surprisingly, the administration of pindolol (a beta(1)+beta(2)-receptor antagonist) enhanced VP secretion.	Pindolol	36-44	arginine vasopressin	Rattus norvegicus	94-96
18194152-8	2008	Pindolol produced a dose-dependent decrease in the buspirone prolactin response.	Pindolol	0-8	prolactin	Homo sapiens	61-70
18054209-1	2008	Pindolol, a 5-HT1A autoreceptor antagonist, given in combination with selective serotonin reuptake inhibitors (SSRIs), may enhance and/or accelerate the therapeutic efficacy of SSRIs.	Pindolol	0-8	5-hydroxytryptamine receptor 1A	Homo sapiens	12-18
17928105-4	2008	The 5-HT(1A) receptor antagonist pindolol has been used to accelerate the clinical effects of antidepressant by preventing the negative feedback.	Pindolol	33-41	5-hydroxytryptamine receptor 1A	Homo sapiens	4-21
17804228-1	2007	Analogues of pindolol, 1-(1H-indol-4-yloxy)-3-isopropylamino-propan-2-ol, were synthesized and evaluated as 5-HT(1A) receptor antagonists.	Pindolol	13-21	5-hydroxytryptamine receptor 1A	Homo sapiens	108-125
17828453-4	2007	[(125)I]Pindolol ([(125)I]PIN) binding studies showed a gradual increase in the specific binding to beta(2)-AR when observed at 5, 10, 15, and 20 days under both cultural conditions.	Pindolol	8-16	adrenoceptor beta 2	Homo sapiens	100-110
17804228-1	2007	Analogues of pindolol, 1-(1H-indol-4-yloxy)-3-isopropylamino-propan-2-ol, were synthesized and evaluated as 5-HT(1A) receptor antagonists.	Pindolol	23-72	5-hydroxytryptamine receptor 1A	Homo sapiens	108-125
17200914-6	2007	Since the mid-nineties it has been attempted to improve the efficacy of antidepressant agents by means of the 5-HT-(1a)-receptorantagonist pindolol.	Pindolol	139-147	5-hydroxytryptamine receptor 1A	Homo sapiens	110-118